News

Happy new year 2026

Mon, 12 Jan 2026 15:02:34 GMT

January 1st 2026

As we begin this new year, we reaffirm our commitment to accelerate discoveries and hope that our research will have meaningful impacts for people living with diabetes.

Thank you to our collaborators and supporters for their continued trust and involvement.

Stay tuned to discover more!

World Diabetes Day 2025 - Let's focus on our ongoing research this past year.

Fri, 14 Nov 2025 13:50:00 GMT

November 14, 2025

It's World Diabetes Day!

Today, we join the global community in raising awareness on diabetes.

Our lab is committed to advance futher scientific knowledge and develop innovative solutions in order to understand more, prevent, and, one day, cure diabetes!

Let's focus on our ongoing research this past year (below).

We would like to thank all our partners and all our supports.

Together, we can accelerate scientific research, make a world where diabetes is no longer a global threat.

PhD Thesis at CeeD: Impact of exerkines in adipocyte functions and their implication in adipose tissue – pancreas crosstalk in a context of type 2 diabetes.

Tue, 28 Oct 2025 23:00:00 GMT

October 29 2025

Congratulations to Daphné BERNARD, who just successfully defended her PhD thesis.

Congratulations to her for achieving this important milestone! CeeD's team is proud of her accomplishments and her involvement throughout her studies.

Impact of exerkines in adipocyte functions and their implication in adipose tissue – pancreas crosstalk in a context of type 2 diabetes.

By Daphné BERNARD

Supervised by Dr. Karim BOUZAKRI from Strasbourg University (DIATHEC – UR 7294) and Pr. Ariane SULTAN from Montpellier University Hospital

Thesis defense jury members:

Dr. Ildiko SZANTO from Genève University Hospital
Dr. Anne BOULOUMIE-DIEHL from INSERM, I2MC, Toulouse University
Pr. Emmanuel VAN OBBERGEN from Nice University Hospital and CNRS, LP2M, Côte d’Azur University
Pr. Florence TOTI from INSERM, CRBS, Strasbourg University

Abstract :

“Type 2 Diabetes (T2D) is qualified as a global pandemic. Obesity represents a high-risk factor in this disease where dysfunctional adipose tissue plays a major role in the onset of T2D. A change in adipocyte secretions in a pathological context is increasingly associated with pancreatic Beta cell damage, emphasizing the need to explore adipose tissue – pancreas crosstalk. Physical exercise, one of the first recommendation for patient care, represents a promising treatment attributed to the secretion of exerkines. Research works in our lab focus on an exercise-induced myokine ILV-001, demonstrated benefits on human pancreatic islets health. The first objective of this study was to investigate the impact of ILV-001 in adipocyte functions, involving the development of a 2D in vitro model of human adipocytes derived from primary culture. We have highlighted a dual role for the myokine depending on the metabolic profile notably suggested a reactivation of adipocyte metabolic functions in a T2D context. The evaluation of adipocyte secretions after a treatment with ILV-001 suggested the implication of an autocrine communication. Then, we examined the impact of these secretions on human pancreatic islets and demonstrated once again a dual role for ILV-001: a capacity to potentiate insulin secretion caused by adipocyte secretions for T2D islets. This research has enabled an in-depth understanding of the mechanisms underlying the benefits of physical exercise through the effect of the exerkine, ILV-001, on adipocyte functions and its involvement in pancreatic islet communication. To further explore the impact of post-exercise secretions, a translational research project has been initiated in collaboration with Montpellier University Hospital.”

Highlights

During her time at CeeD, Daphné Bernard had several opportunities:

January 2024: Invitation by Pr. Mikael Rydén (Member of her PhD committee follow-up) for a two-week internship in his Lab “Lipid Lab” (Karolinska Institutet, Stockholm, Sweden). Objectives: Optimize progenitor adipocyte isolation from human samples.

March 2024: Société Francophone du Diabète (SFD) scientific congress

Research grant Laureate – 2024 – Clinical research for the implementation of DIABETEX project aiming to study the impact of post-exercise secretions on human pancreatic islet (in collaboration with Pr. Ariane SULTAN, CHU Montpellier).
Interview given to “Diabète et Obésité” journal to present DIABETEX project.
Discussed and posted communication : “Myokine X, une nouvelle piste thérapeutique dans le diabète de type 2”. D. Bernard, J. Vion-Chambrial, M. Pinget, A. Sultan, K. Bouzakri

June 2024: Scientific sessions of the American Diabetes Association (ADA) 2024 in Orlando, USA. Poster presented: “Myokine X, a new therapeutic approach for type 2 diabetes”. D. Bernard, J. Vion-Chambrial, M. Pinget, A. Sultan, K. Bouzakri.

PhD Thesis at CeeD: Study of the impact of extracellular vesicles in the process of Human pancreatic islet transplantation

Fri, 10 Oct 2025 13:28:42 GMT

October 10 2025

Congratulations to Hanae Talbi, a fellow PhD student!

She successfully defended his PhD thesis at CeeD's amphitheater in Strasbourg. Well done! To her success and all the work that led her here.

Study of the impact of extracellular vesicles in the process of Human pancreatic islet transplantation

By Hanae Talbi

Supervised by Dr Karim Bouzakri

Summary:

Pancreatic islet transplantation is a promising therapy to restore glycemic control in patients with type 1 diabetes. However, the grafted islets are destroyed, partly due to an inflammatory and pro-coagulant response (IBMIR) induced during the transplantation procedure. To improve islet survival and function, we analyzed the role of extracellular vesicles (EVs) released by human pancreatic islets, cultured under physiological or pro-inflammatory conditions, and their effects on immune cells. We first isolated and characterized EVs from human islets comparing two extraction techniques. We then evaluated their ability to activate macrophages and monocytes using a human monocyte cell line (THP-1). In addition, we analyzed the transcriptomic and post-transcriptomic changes induced by EVs in monocytes. Finally, we isolated EVs from murine islets to use them during an in vivo study.

Our findings show that EVs induce distinct transcriptomic profiles in monocytes depending on their inflammatory origin. Pro-inflammatory EVs inhibited several genes in the hsa04080 pathway, including HTR2A, the serotonin receptor. We have demonstrated that the regulation of HTR2A by EVs is mediated by a novel microRNA (Novel_239). In addition, proinflammatory EVs amplified serotonin activity by increasing TNF-α expression. Serotonin is a neurotransmitter known for its role in modulating inflammation. It is released by several cell types, including pancreatic islet cells, monocytes, and hepatocytes. The interaction between EVs and serotonin during transplantation may worsen islet inflammation and partly cause graft loss. Finally, we showed that EVs from murine islets do not reflect the properties of human EVs and therefore not suitable for in vivo studies.

Thank you to the thesis defense jury members:

Dr Ildiko Szanto from University of Geneva
Dr Stéphane Dalle from Montpellier University
Dr Florence Toti from Strasbourg University
Dr Amar Abderrahmani from Lille University
Dr Karim Bouzakri from CeeD

New postdoc on the benefits of resistance training upon beta-cells and the molecules involved in this process

Tue, 16 Sep 2025 09:22:27 GMT

September 1 2025

Welcome Gabriela Alves Bronczek!

Gabriela, our new postdoc, just arrived from the Obesity and Comorbidities Research Center of Universidade Estadual de Campinas , Brazil.
She will study the benefits of resistance training upon beta-cells and the molecules involved in this process.

She joins our team for one year thanks to a Post-Doctoral fellowship granted by the Sao Paulo Research Foundation.

Discover the research project:

Identification of small molecules and exosomes in the serum of resistance-trained mice.

Abstract : Exercise induces the release of various molecules, called exerkines, into the bloodstream that play important roles in different tissues, especially the endocrine pancreas. Moreover, extracellular vesicles (EVs), including microvesicles (MVs) and exosomes or exosome-like vesicles (ELVs), are secreted concomitantly with exerkines. These EVs act as cargo carriers or ‘mediators’ of intercellular communication. Thus, there has been a growing interest in the role of EVs on the organ crosstalk in response to exercise. In previous studies, we observed that INS-1E cells (rat pancreatic beta cells) treated with the serum from resistance-trained mice secrete more insulin in response to glucose. In addition, these cells are more resistant to injury and apoptosis induced by endoplasmic reticulum (ER) stress and pro-inflammatory cytokines. Thus, we believe that these alterations are mediated by exercise-induced molecules released in the bloodstream. Next, we analyzed the serum from resistance-trained mice to identify the mediator of such effects. We were able to determine that this mediator is smaller than 3 kDa and is not a protein. Given the rising interest on exosomes, their small size and their content, investigate the involvement of this type of EV on the effects of resistance exercise on beta cells may be an interesting approach to unravel the mediator we have been looking for. In this context, this project aims to identify small molecules such as metabolites, and exosome content that may benefit beta cell function. For this, we will perform a metabolomic analysis by mass spectrometry, as well as exosome isolation on the serum from resistance-trained mice. Thus, we will be able to select molecules and isolate exosomes to test their effects in vitro, by treating human pancreatic islets and sorted beta cells. We believe that the characterization of such molecules could be of great therapeutic interest, especially for T1D individuals, contributing to maintaining their glycemic control, as well as their remaining beta cells.

Advisor: Antonio Carlos Boschiero, PhD - Obesity and Comorbidities Research Center (OCRC)/IB/Unicamp/Brazil.
RIA Supervisor: Karim Bouzakri, PhD - Centre européen d'étude du Diabète (CeeD)/UR DIATECH 7294-University of Strasbourg/France.

New publication on Exerkines: a review of Physical Exercise as a Therapeutic Approach for Type 2 Diabetes

Tue, 02 Sep 2025 09:10:37 GMT

August 25 2025

Physical Exercise as a Therapeutic Approach for Patients Living with Type 2 Diabetes: Does the Explanation Reside in Exerkines? - A Review

Bernard D., Sultan A., Bouzakri K.

Diabetes mellitus, whose main form type 2 diabetes (T2D) accounts for 90% of all cases, is now recognized as a widespread pandemic mainly attributed to the rise in Western diet consumption. The disease relies on a default of insulin action in insulin sensitive tissues, known as insulin resistance, which can lead to Beta cell death and finally chronic hyperglycemia. To date, there is no treatment available to cure the disease.

However, lifestyle modifications, including eating behaviors and increasing physical activity, represent the first recommendations for managing T2D. For a few decades, a crosstalk seems to be involved in physical exercise with the secretion of molecules defined as “exerkines”. Thus, the review intends to first summarize the current knowledge related to physical exercise benefits in a context of T2D: from “unwanted” adipose tissue reduction to Beta cell health improvement. Then, a possible underlying mechanism explaining the beneficial effects of physical exercise through exerkine secretions, with a particular focus on pancreatic cells, is explored.

Because of the need for regulatory authorities to reduce the use of animals for scientific purposes, particular emphasis is placed on clinical studies.

Link to the paper : https://www.mdpi.com/1422-0067/26/17/8182

Scientific sessions of the American Diabetes Association (ADA) 2025 in Chicago, USA

association@ceed-diabete.org (Claire MASALSKI) — Tue, 24 Jun 2025 07:49:12 GMT

June 20-23 2025

Dr Karim Bouzakri, our laboratory director, and Dr Allan Langlois, associate lab director, were in Chicago for one of the world's largest diabetes congress organized by the American Diabetes Association (ADA).

At this occasion, Dr Allan Langlois presented our project, which focuses on islet transplantation and a promising therapeutic approach for people with unstable T1DM:

ILV-001, a Myokine of Interest to Potentiate the Success of Pancreatic Islet Transplantation and Treat a Maximum Number of People with T1DM

The main challenge is to reduce the number of pancreases needed to treat a single person. In this context, we have recently demonstrated that ILV-001, a component of the muscle secretome, enables rapid uptake and lasting function of the graft. The aim of the project was to determine whether ILV-001 could reduce the pancreatic islets quantity to be transplanted in order to normalize glycemia. To this end, we have injected 5000 IEQ/kg untreated (control group) or pre-treated with 1µg/ml ILV-001in the liver of diabetic syngeneic rats via the portal vein. Either transplanted animals received or not a daily intraperitoneal injection of ILV-001. A metabolic follow up was performed for 3 months (Weight gain, glycemia, c-peptidemia, graft function). Interestingly, we demonstrated that whatever ILV-001 administration modality, our myokine potentiates effectiveness of islet transplantation and allows to reduce by at least half the number of islets needed to normalize glycemic control in diabetic rats.

CeeD was at the previous American Diabetes Association (ADA) scientific sessions:

PhD Thesis at CeeD: Impact of the myokine ILV001 on MASLD and MASH

association@ceed-diabete.org (Claire MASALSKI) — Tue, 10 Jun 2025 12:45:55 GMT

June 16 2025

Congratulations to Jean-Baptiste Potier, a fellow PhD student from our spin-off ILONOV and our university lab UR DIATHEC 7294! JB successfully defended his PhD thesis last June 16 at CeeD's amphitheater in Strasbourg.

CeeD's team is very proud of his achievement and wishes him a great career in research for the years to come!

Impact of the myokine ILV001 on the prevention of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH)

By Jean-Baptiste Potier

Supervised by Dr Karim Bouzakri from ILONOV and UR DIATHEC 7294 (CeeD) at Strasbourg University

Thesis defense jury members:

Dr Catherine Schuster from Strasbourg Université
Pr Jean-François Gautier from INSERM, Assistance Publique - Hôpitaux de Paris
Pr Niklas Björkström from Karolinska Institutet

Summary:

« Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH) are rapidly becoming the most common liver disease in the world, mainly as a consequence of the pandemic of type 2 diabetes, genetic factors and sedentary lifestyle. However, the available therapeutic options for patients are highly limited since no drug has been globally approved. Thus, physical exercise and lifestyle intervention are the first line of treatment for these diseases. The molecular mechanisms behind the benefits of physical activity have been widely studied but some aspect still remains unexplored. During the past decades, a new role for skeletal muscle as a secretory organ has been described, through its ability to secrete factors during contraction, called myokines . In this context, these myokines could play a critical role of mediator of the benefits of exercise on whole-body homeostasis.

During this PhD project, we aimed at extending the current knowledge on the role of the liver-muscle crosstalk in the context of metabolic disease. Using human-derived 3D liver models of MASLD and MASH, we studied the role of one muscle secreted myokine, ILV001, in the pathophysiology of these diseases. Our study with cells of different human donors suggest that this myokine may be a critical mediator of the positive impact of exercise on liver metabolism and could represent a promising therapeutic potential for patients suffering of chronic liver diseases. »

Distinctive features of this PhD project

This work is the result of a CIFRE collaboration between the University of Strasbourg's DIATHEC laboratory at the Centre européen d'étude du Diabète and ILONOV, a biotech company aiming to exploit the potential of the muscle secretome for the treatment of metabolic diseases.

The CIFRE (Conventions Industrielles de Formation par la Recherche) scheme, set up by the ANRT (Association Nationale de la Recherche et de la Technologie), aims to encourage exchanges between the business world and public academic research.

This project was also made possible thanks to a collaboration with the Center for Infectious Medicine at the Karolinska Institutet in Stockholm, which helped in setting up the 3D human liver model.

Throwback

During his thesis, Jean-Baptiste had the opportunity to go to different congress and research events. He presented at the 58th EASD Annual Meeting (European Association for the Study of Diabetes) in Stockholm (SE) on September 22, 2022 about :

Skeletal muscle derived myokine affects insulin sensitivity and lipogenesis in a human hepatocyte spheroid model

Société Francophone du Diabète (SFD) 2025 in Paris, FR

association@ceed-diabete.org (Claire MASALSKI) — Thu, 03 Apr 2025 14:55:03 GMT

April 1-4 2025

Hanae Talbi, PhD student at CeeD, Dr Karim Bouzakri, our laboratory director, and Dr Allan Langlois, associate lab director, were in Paris for this major medical congress organized by the French-speaking Diabetes Society (SFD).

3 avril, 13:10 | Session Communication affichée et discutée : Greffe et technologies innovantes (2) | Hall Bordeaux - espace 3

" Rôle des vésicules extracellulaires des îlots pancréatiques dans la réponse inflammatoire associée à la procédure de transplantation chez les patients diabétiques de type 1 " - Hanae Talbi, doctorante

3 avril, 16:30 | Session Communication orale : Greffe, thérapie cellulaire | 141

" ILV-001, une myokine d’intérêt pour potentialiser le succès de la transplantation d’îlots pancréatiques et traiter un maximum de personnes atteintes de DT1 " - Dr Allan Langlois

4 avril, 09:00 | Symposium sur le contrôle de la masse et de la fonction des cellules bêta | 142-143

" Dialogue entre muscle squelettique et cellule bêta " - Dr Karim Bouzakri

ILV-001, une myokine d’intérêt pour potentialiser le succès de la transplantation d’îlots pancréatiques et traiter un maximum de personnes atteintes de DT1

Allan Langlois 1, Michel Pinget 1, Siobhan Craige 2, Karim Bouzakri 3

1- Ur « Diabète Et Thérapeutiques », Centre Européen D’étude Du Diabète, Université De Strasbourg - Strasbourg (France)

2 - Department Of Human Nutrition, Foods, And Exercise, Virginia Tech, Blacksburg, Virginia, Usa. - Blacksburg, Virginia (États-Unis) 3 - Ur « Diabète Et Thérapeutiques », Centre Européen D’étude Du Diabète, Université De Strasbourg; Ilonov - Strasbourg (France)

OBJECTIF

La transplantation d'îlots pancréatiques est une approche prometteuse pour traiter les personnes atteintes de DT1 instable. Le challenge principal est de réduire le trop grand nombre de pancréas à utiliser pour traiter une seule personne. Dans ce contexte, nous avons récemment démontré que ILV-001, un composant du sécrétome musculaire, permettait une prise rapide et une fonction durable de la greffe. Le but du projet était de déterminer si ILV-001 permettait de réduire la quantité d’îlots pancréatiques à transplanter nécessaire pour normaliser la glycémie chez le rat rendu diabétique.

MATERIELS-ET-METHODES

Des rats syngéniques rendus diabétiques avec de la streptozotocine, ont reçu ou non (groupe SHAM) une perfusion intra portale de 5000 IEQ/kg non traité (groupe contrôle) ou prétraités avec 1μg/ml d’ILV-001. Les animaux transplantés ont reçu ou non une injection intra péritonéale (IP) quotidienne d’ILV-001. Pendant 3 mois, prise de poids, glycémie, besoins en insuline, c-peptidémie et fonction du greffon ont été évaluées.

RESULTATS

La transplantation de 5000IEQ/kg n’a pas permis d’améliorer la glycémie par rapport au SHAM. En revanche, 5000IEQ/kg + ILV-001 améliore significativement le contrôle glycémique des rats diabétiques dès 3 jours post-transplantation, comme précédemment obtenu avec l’injection de 10 000 IEQ/kg. Quel que soit la modalité d’administration d’ILV-001, la c-peptidémie est augmentée par rapport au groupe contrôle à partir de 7 jours post-injection. De plus, les tests IPGTT ont montré une meilleure fonctionnalité du greffon avec ILV-001 par rapport aux contrôles tout au long de l’étude. Enfin, les besoins en insuline ont été significativement diminués pour les rats traités avec ILV-001 durant toute la durée du suivi métabolique.

CONCLUSION

ILV-001 est un agent thérapeutique prometteur pour potentialiser l’efficacité de la transplantation d’îlots. Elle permet de réduire d’au moins de moitié la quantité d’îlots

Rôle des vésicules extracellulaires des îlots pancréatiques dans la réponse inflammatoire associée à la procédure de transplantation chez les patients diabétiques de type 1

TALBI Hanae ¹ , RIDA Ahmad ² , BOUZAKRI Karim ^1,2

¹ UMR DIATHEC, EA 7294, Centre européen d'étude du Diabète, Université de Strasbourg, France

² ILONOV, Strasbourg, France

ABSTRACT

La transplantation des îlots pancréatiques est une thérapie qui vise à restaurer un contrôle glycémique chez les patients diabétiques de type 1. Cependant, les îlots greffés sont détruits en partie à cause d’une réponse inflammatoire et pro-coagulante précoce (IBMIR) induite lors de la procédure de transplantation. Dans le but d’améliorer la survie et la fonction des îlots, notre étude s'intéresse à la fonction des vésicules extracellulaires (EVs) libérées par les îlots en phase de culture pré-transplantation et à leur impact sur la réponse immunitaire des monocytes.

Pour cela, des îlots pancréatiques humains ont été cultivés dans un milieu physiologique dépourvu d’EVs (Contrôle) ou dans un milieu pro-inflammatoire (Cytomix). Les EVs des surnageant de culture ont été extraites puis caractérisées par microscopie électronique à transmission, western blot et analyse de distribution de taille par DLS. Ces EVs ont ensuite été utilisées pour traiter des monocytes humains THP-1. Après le traitement, l’expression de cytokines a été quantifiée par RT-qPCR et la différenciation des monocytes adhérents a été évaluée par microscopie à fluorescence, suite à un co-marquage CD86 (M1)/CD163 (M2) avec une coloration au DAPI. De plus, un séquençage d’ARN a été réalisé sur l’ARN extrait à partir des monocytes traités aux EVs Contrôle et Cytomix.

Les observations en microscopie ont révélé une prolifération importante des monocytes traités avec les EVs Cytomix, accompagnée d’une concentration d’ARN significativement élevée par rapport aux autres conditions. La quantification des gènes par RT-qPCR a mis en évidence une diminution significative du TNF-alpha et du TGF1-bêta dans les monocytes EVs Cytomix. A l’inverse, les monocytes traités aux EVs Contrôle ont montré une forte adhérence et une co-expression des marqueurs CD86/CD163, suggérant un début de différenciation des monocytes.

Ainsi, nos résultats montrent que les EVs dérivées d’îlots influencent différemment les monocytes selon leur environnement d’origine. Une analyse plus approfondie de la réponse transcriptionnelle par séquençage d’ARN est en cours afin d’élucider les mécanismes moléculaires impliqués et leur impact potentiel sur la réponse inflammatoire.

Références bibliographiques

Abels & Breakefield, 2016. Cellular and Molecular Neurobiology.
Elsharkasy et al., 2020. Advanced Drug Delivery Reviews.
Kin T, 2010. Advances in Experimental Medicine and Biology.
Nilsson, Ekdahl & Korsgren, 2011. Current Opinion in Organ Transplantation.
Piemonti et al., 2022. PLOS ONE.
Shapiro et al., 2000. The New England Journal of Medicine.
Trovato, Di Felice & Barone, 2019. Frontiers in physiology.
Welsh et al., 2024. Journal of extracellular vesicles.
Yan et al., 2022. Immunology.

CeeD was at the previous editions of SFD congress:

...

New publication on DECORIN, a triceps-derived myokine, and type 2 diabetes on Acta Physiol (Oxf)

association@ceed-diabete.org (Claire MASALSKI) — Thu, 30 Jan 2025 10:54:49 GMT

January 30 2025

"DECORIN, a triceps-derived myokine, protects sorted β-cells and human islets against chronic inflammation associated with type 2 diabetes"

Langlois A, Cherfan J, Meugnier E, Rida A, Arous C, Peronet C, Hamdard H, Zarrouki B, Wehrle-Haller B, Pinget M, Craige SM, Bouzakri K

A good news to start the year: CeeD laboratory reveals a new publication in Acta Physiologica journal

In this paper, the research team shows that DECORIN, a new triceps-derived myokine, has a beneficial effect on human pancreatic islets, protecting them from cell death induced by inflammation.
This work demonstrates for the first time that DECORIN restores T2D-islet function and reverses the expression of T2D-associated genes.
Based on these datas, they propose DECORIN as a promising therapeutic target for diabetes-associated inflammation and diabetes itself.

Link to the paper and abstract:

https://pubmed.ncbi.nlm.nih.gov/39844653/

Happy new year 2025

association@ceed-diabete.org (Claire MASALSKI) — Tue, 07 Jan 2025 15:47:11 GMT

January 1st 2025

CeeD, Vaincre le diabète , and its spin-off, ILONOV and CEED Formation , wish you a happy new year.

A little touch of humor to start 2025…

This year, we asked AI to generate our greeting card. Our instructions: represent our fight against diabetes and carry a message of hope, unity and innovation. According to the tool, this scene would harmoniously illustrate research, patient care and health professionals training. We let you judge the result ��

Thank you for your support and your generosity.

World diabetes day - our members share the best publications on diabetes in 2024

association@ceed-diabete.org (Claire MASALSKI) — Wed, 13 Nov 2024 12:15:24 GMT

November 14 2024

On this special day, CeeD and ILONOV (our spin-off) share with you some of the best publications/discoveries on diabetes since the beginning of the year: outstanding breakthroughs to go futher in our knowledges on diabetes and closer to a cure for patients!

Indeed, we want to praise all research projects, as every discovery matters and needs to be highlighted on a larger scale and because scientists can not work alone on such a large and complex topic.

Discover some members of CeeD and ILONOV (our spin-off) teams

New publication about Islet transplantation on Cells

association@ceed-diabete.org (Claire MASALSKI) — Tue, 29 Oct 2024 11:11:41 GMT

October 29 2024

"Islet transplantation: current limitations and challenges for successful outcomes"

Langlois A, Pinget M, Kessler L, Bouzakri K

This work was the occasion to provide an overview of recent scientific findings on the various mechanisms affecting islet transplantation and to discuss about promising strategies developed to alleviate these issues from isolation stage to post-transplantation phase. We hope that this review will highlight new avenues of action, enabling us to propose pancreatic islet transplantation to a maximum number of patients with T1DM.

Link to the pap er and abstract: https://www.mdpi.com/2073-4409/13/21/1783

New publication on NADPH oxidases in healthy white adipose tissue and in obesity

association@ceed-diabete.org (Claire MASALSKI) — Mon, 07 Oct 2024 09:44:05 GMT

September 24 2024

"NADPH oxidases in healthy white adipose tissue and in obesity: function, regulation, and clinical implications"

Jornayvaz FR, Gariani K, Somm E, Jaquet V, Bouzakri K, Szanto I.

NADPH oxidase (NOX)- and dual oxidase (DUOX)-enzymes produce oxidant entities and were recently recognized as novel regulators of white adipose tissue physiological functions and their adaptation in obesity. Our review provides and up-to-date summary of the physiological roles of NOX/DUOX enzymes in healthy metabolism and the pathological alterations associated with their dysfunctions, particularly the onset of Type 2 diabetes.

Our review draws attention to a novel component of Type 2 diabetes development that should be further investigated to provide more precision targeting in the treatment of diabetes and obesity.

Link to the paper and abstract: NADPH oxidases in healthy white adipose tissue and in obesity: function, regulation, and clinical implications - PubMed (nih.gov)

Scientific sessions of the American Diabetes Association (ADA) 2024 in Orlando, USA

association@ceed-diabete.org (Claire MASALSKI) — Tue, 25 Jun 2024 13:51:05 GMT

June 21-24 2024

Daphné Bernard, one of our PhD students, was in Orlando for one of the world's largest diabetes congress organized by the American Diabetes Association (ADA). She presented her project, which focuses on the impact of Myokine X on adipose tissue of a type 2 diabetes rodent model. This well-known scientific session was a great opportunity to highlight our latest work on the effects of our “Myokine X”.

As you may know, our team discovered that:

a crosstalk exists between the muscle and the pancreas in a context of type-2 diabetes
the muscle’s secretome (the triceps in particular) during resistant exercise has beneficial effects on the pancreas. The team especially puts forward the positive effects of one myokine, the Myokine X, on β-cell survival and function.

In this context, Daphné Bernard’s PhD project aims to study the effect of the Myokine X on adipose tissue - pancreas crosstalk in the context of type-2 diabetes. This study is even more relevant since one of type-2 diabetes’ complication is the energy imbalance that induces adipose tissue dysfunction causing disease worsening and complications. Thus, it is necessary to find new therapies targeting adipose tissue.

Abstract

Myokine X, a new therapeutic approach for type 2 diabetes

D. Bernard ¹ , J.Vion-Chambrial ² , M. Pinget ^1,2 , A. Sultan ^3,4 , K. Bouzakri ^1,2

¹ Centre européen d’étude du Diabète, Unité Diabète et Thérapeutique (DIATHEC) – UR7294, 67200 Strasbourg, France

² ILONOV, 67200 Strasbourg, France

³ PhyMedExp, INSERM U1046, CNRS UMR 9214, Université de Montpellier, 34000 Montpellier, France

⁴ Département Nutrition-Diabète, Centre hospitalier universitaire de Montpellier, 34295 Montpellier, France

In a context of hyperglycaemia and excess of fatty acid intake leading to the disease, adipose tissue functions are dysregulated. We have already demonstrated the beneficial impact of Myokine X on pancreatic islets survival and functionality. This study aims to investigate the impact of Myokine X, which is secreted after a resistance effort, on adipose tissue of a rodent model of T2D.

Zucker Diabetic Sprague-Dawley (ZDSD) rat, naturally developing type 2 diabetes, received a daily peritoneal injection of either a saline solution (control group) or a Myokine X solution at 1 µg/mL for 20 weeks. Animals were sacrificed at the end of the 20 weeks and adipose tissue was analysed by western blotting or by qPCR for gene expression. The significance of the data was assessed using Student's t test to compare two conditions. When several factors were present, two-way ANOVAs were performed.

Myokine X treatment revealed (i) an impact on insulin pathway with an increase of 16.5% of Akt p-ser473 phosphorylation capacity, with simultaneously a significant increase of 78% for GLUT4 mRNA expression, (ii) a significant decrease of HSL phosphorylation on ser660 (-24%), (iii) an increase of adipokines mRNA expression with beneficial impact on insulin pathway.

This study shows that Myokine X treatment had a positive impact on adipose tissue in a rodent model of T2D, in terms of insulin sensitivity improvement, HSL activation decrease and improvement of adipose tissue secretion, adipokines. Thus, Myokine X could represent a therapeutic approach for T2D treatment.

Press release

association@ceed-diabete.org (Claire MASALSKI) — Thu, 30 May 2024 14:24:50 GMT

May 29 2024

REPLAY Télématin

A popular early morning TV show in France, “Télématin” (France 2), focused on our research study on the triceps.

A nice highlight for diabetes and medical research from a siginificant platform!

For those who missed it, catch our segment :

Quality audit: ISO certification renewal

association@ceed-diabete.org (Claire MASALSKI) — Wed, 22 May 2024 13:13:50 GMT

June 11 2024

CeeD is proud of its new certification ISO9001:2015, covering all its activities for the next 3 years.

Thank you to our teams for their involvement and participation during the audit compliance made by the DQS organization, DQS Medizinprodukte GmbH.

Congratulations to Harzo Hamdard, our quality director, for this nice feedback from our auditor:

0 non-compliance detected
5 strengths emerged from our organization and fundamental and applied research management: prevention and screening activity, quality system management, animal facility and CeeD’s development and management strategy.

New grant from Société Francophone du Diabète (SFD) 2024

association@ceed-diabete.org (Claire MASALSKI) — Thu, 28 Mar 2024 10:24:39 GMT

March 19-22 2024

A new research grant for CeeD and its partner

During the French-speaking Diabetes Society (SFD) congress, Dr Karim Bouzakri, our laboratory director, and Daphné Bernard, PhD student, were grateful to receive the clinical research grant for a clinical protocol “DIABETEX - Study of the impact of exercise on pancreatic islet functionality and survival in subjects living with type 2 diabetes” conducted as part of Daphné’s PhD project in collaboration with Montpellier University Hospital, with Daphné’s PhD co-director, Pr. Ariane SULTAN.

The congress enabled them to take the opportunity to thank the SFD scientific board for the confidence they have shown in the project and the progress it will bring to our research work.

Spotlight on the DIABETEX project

At this occasion, Daphné presents the project in front of the French multidisciplinary journal “Diabète et Obésité”.

Société Francophone du Diabète (SFD) 2024 in Toulouse, FR

association@ceed-diabete.org (Claire MASALSKI) — Thu, 28 Mar 2024 10:15:52 GMT

March 19-22 2024

Dr Karim Bouzakri, our laboratory director, and Daphné Bernard, PhD student, were in Toulouse for this major medical congress organized by the French-speaking Diabetes Society (SFD).

Daphné Bernard presented her study consisting in studying the impact of a myokine secreted by muscle after physical exercise, the Myokine X (MyoX), on adipose tissue of a type 2 diabetes (T2D) rodent model.

This work is integrated in her PhD project with the aim of studying the role of physical exercise on adipose tissue – pancreas crosstalk in a context of diabetes. Indeed, an energy imbalance is often involved in the type-2 diabetes and leads to adipose tissue dysfunction worsening the disease and leading to complication. Thus, the need to find new therapies, targeting adipose tissue, is necessary.

This was for Daphné her first opportunity to present her work in a congress. Apart from having a chance to present her project in front of other specialists, the different talks she attended were also instructive for the continuation of her project.

Abstract :

Myokine X, a new therapeutic approach for type 2 diabetes

Introduction:

Type 2 diabetes is now recognized as a major public health issue. In a context of hyperglycaemia and excess of fatty acid intake leading to the disease, adipose tissue functions are dysregulated. We have already demonstrated the beneficial impact of Myokine X on pancreatic islets survival and functionality. This study aims to investigate the impact of Myokine X, which is secreted after a resistance effort, on adipose tissue of a rodent model of T2D.

Material and methods : Zucker Diabetic Sprague-Dawley (ZDSD) rat, naturally developing type 2 diabetes, received a daily peritoneal injection of either a saline solution (control group) or a Myokine X solution at 1 µg/mL for 20 weeks. Animals were sacrificed at the end of the 20 weeks and adipose tissue was analysed by western blotting or by qPCR for gene expression.

Results:

Conclusion:

Collaboration with the Karolinska Institutet, 2024

Thu, 08 Feb 2024 12:45:52 GMT

In the framework of her thesis follow-up committee. Daphné Bernard, PhD student at CeeD, was invited in the lab of Pr. Mikael Rydén, the Lipid laboratory at the Karolinska Institutet to optimize adipocyte isolation and culture from human biopsy.

Adipose tissue is considered as the main tissue of lipid storage, allowing the release of fuel when organism need it (Fasting period, exercise). In a context of an excess of free fatty acid and glucose uptake, this tissue can be damaged leading to insulin resistance and finally to type 2 diabetes. Most specifically in this project, this in vitro adipocyte model will be integrated in a clinical study to evaluate the role of physical exercise in the crosstalk between adipose tissue and pancreas in a context of diabetes. In fact, exercise now represents one of the main recommendations for patients living with type 2 diabetes and adipose tissue secretion seems to be involved in the mechanisms underlying exercise benefits.

International Pancreatic Islet Transplantation Association (IPITA), 2023 in San Diego, USA

Wed, 13 Dec 2023 14:44:21 GMT

October 26-29, 2023

Dr Karim Bouzakri, our laboratory director

Dr. Karim Bouzakri, gave a talk on advences in cell therapy and islet transplantation for Type 1 diabetes.

Abstract :

ILV-001 a highly promising therapeutic agent for islet transplantation

A. Langlois ¹ , A. Grabarz ² , M. Pinget ^1,2 , K. Bouzakri ^1,2

1. DIATHEC, UMR 7294, Centre européen d’étude du Diabète, Université de Strasbourg, Boulevard Leriche, 67200 Strasbourg, France.

2. ILONOV, Boulevard Leriche, 67200 Strasbourg, France.

Introduction:

Our team has shown a bimodal effect on β-cells of muscle-secreted myokines from normal or insulin-resistant human skeletal muscle. We identified ILV-001, a component of the muscle secretome regulated by muscle fiber type and physical exercise, moreover naturally present in the extracellular matrix of the islet niche. Thus, we aimed at investigating the therapeutic potential of ILV-001 in protecting β-cell function and survival during islet transplantation.

Methods:

In vitro: Rat islets were incubated 24h ± ILV-001 (1µg/mL). Islet survival was assessed by TUNEL assay ± cytomix. Islet function was evaluated using GSIS test.

In vivo: 10000 IEQ/kg ± ILV-001 were injected intraportaly in diabetic syngeneic rats. For 3 months body weight gain, glycaemia, c-peptidemia and graft function (IPGTT) were followed. Inflammation was evaluated titrating plasmatic α ₂ -macroglobulin. Histology was performed on grafted islets.

Results:

In vitro: ILV-001 improves islet function and survival and potentiates insulin secretion after GSIS test.

In vivo: ILV-001 improves graft function in terms of glycaemia (p<0.001) and c-peptidaemia (p<0.01) and decreases exogenous insulin intake requirements. ILV-001 reduced inflammation 24h post graft with a lower plasmatic α ₂ -macroglobulin versus control with respectively 459±70 versus 903±191 µg/mL (p<0.05). Finally, histology showed a preservation of insulin positive cells with ILV-001 versus control at the end of study (69±3% versus 39±3% of β-cells/islet, p< 0.001).

Conclusion:

ILV-001 is a highly promising candidate for the achievement of a functional cure in T1D thanks to potent β-cell preservation and obtaining long term graft maintenance following islet transplant.

European Association for the Study of Diabetes (EASD) 2023 in Hambourg, DE

Wed, 13 Dec 2023 14:43:35 GMT

October 02-06 2023

Dr Karim Bouzakri and Mélissa Yepmo, our scientific team was in Hambourg, Germany for the 59th annual meeting of European Association for the Study of Diabetes (EASD).

Mélissa Yepmo PhD student at CeeD, presented "Unique signature of circular RNA in skeletal muscle of different insulin sensitivity" the October 5, 2023.

Scientific sessions of the American Diabetes Association (ADA) 2023 in San Diego, USA

association@ceed-diabete.org (Claire MASALSKI) — Mon, 26 Jun 2023 12:28:16 GMT

June 23-26 2023

CeeD was in San Diego for the major scientific event of the American Diabetes Association.

With Dr Karim Bouzakri, our laboratory director:

1 - Mélissa Yepmo explained her PhD research on CircRNAs, an emergent class of non coding RNA as new potentiel therapeutic target in skeletal muscle and their role in insulin secretion dysfunction

Abstract :

" Diabetes pathologies are complex, affecting numerous organs such as liver, pancreas, and skeletal muscle. Circular RNAs (circRNA) are a class of non-coding RNAs that are characterized by a covalently closed loop structure. Functionally, they can act on cell physiology by sponging microRNAs and thus regulating gene and protein expression. The emerging function of these circRNA is not fully understood, but initial studies have recently shown that circRNA are involved in insulin secretion regulation. Therefore, deregulation of this class of RNAs may lead to metabolic disorders in pancreatic β-cells and thus be involved in the pathogenesis of type 1 (T1DM) and type 2 diabetes (T2DM). Our research is focused on the unique signature by circular RNA and the impact on skeletal muscle metabolism. We demonstrated that human skeletal muscle cells in culture maintain their gene expression phenotype. A di"erent gene signature of the cells according to their di"erent muscular fiber type sources (oxidative versus glycolytic versus mixt) was confirmed. Moreover, an independent microRNA composition has also been highlighted. As CircRNA can regulate microRNAs and then gene expression and proteins, we wondered whether these observed signatures could be explained by circRNA. We therefore focused on key circRNAs involved in myogenesis (such as circZNF609, circHIPK3) and we were able to see that there is a difference in expression of circRNA according to the muscle type. Moreover, we analyzed correlations between circRNA levels and insulin sensitivity (measured by PKB phosphorylation). Finally, we are currently completing our analysis with in-depth sequencing techniques to identify all expressed circRNA in muscle fiber types to potentially identify new targets in insulin metabolic pathways."

2 - Dr Allan LANGLOIS presented the project untitled “ILV-001 a highly promising therapeutic agent for islet transplantation” (1494-P, session “Beta cells replacement”).

In this work, we aimed at investigating the therapeutic potential of ILV-001, a component of the muscle secretome regulated by physical exercise and naturally present in the extracellular matrix of the islet niche, in protecting β-cell function and survival during islet transplantation.

Abstract :

ILV-001 a highly promising therapeutic agent for islet transplantation

A. Langlois ¹ , A. Grabarz ² , M. Pinget ^1,2 , K. Bouzakri ^1,2

1. DIATHEC, UMR 7294, Centre européen d’étude du Diabète, Université de Strasbourg, Boulevard Leriche, 67200 Strasbourg, France.

2. ILONOV, Boulevard Leriche, 67200 Strasbourg, France.

Introduction:

Methods:

In vitro: Rat islets were incubated 24h ± ILV-001 (1µg/mL). Islet survival was assessed by TUNEL assay ± cytomix. Islet function was evaluated using GSIS test.

Results:

In vitro: ILV-001 improves islet function and survival and potentiates insulin secretion after GSIS test.

Conclusion:

ILV-001 is a highly promising candidate for the achievement of a functional cure in T1D thanks to potent β-cell preservation and obtaining long term graft maintenance following islet transplant.

Collaboration with the Karolinska Institutet, Part 2 - 2023

Sun, 30 Apr 2023 09:48:26 GMT

As part of our collaboration with the Karolinska Institutet, Jean-Baptiste Potier, PhD student at CeeD and ILONOV, had the opportunity to be welcomed a second time at Karolinska Institutet, Stockholm, in order to deepen his skills in 3D cell culture between March and April 2023.

Specifically, the aim was to learn a new method of liver spheroids. The first model comprised only hepatocytes, which is suitable for the study of steatosis and insulin resistance, the main hallmarks of non-alcoholic fatty liver disease (NAFLD), however, in order to study its progression, non-alcoholic steatohepatitis (NASH), and thus inflammation and fibrosis, one should include other liver cell types that are affected above hepatocytes. One of this cell types, hepatic stellate cells, are also present in the liver and are meant to store vitamin A as a quiescent state in healthy individuals. However, once NAFLD progresses and disturbs the hepatic micro-environment, they become activated and produce collagen and inflammatory factors, leading to fibrosis and cirrhosis. Then, the aim of this second trip was to learn how to co-culture hepatocytes and hepatic stellate cells in liver spheroids, in order to focus more on the hallmarks of NASH.

New publication for CeeD and its spin-off ILONOV on Myokines in Nutrients journal

association@ceed-diabete.org (Claire MASALSKI) — Wed, 05 Apr 2023 07:21:53 GMT

April 5, 2023

« Myokines: Crosstalk and Consequences on Liver Physiopathology »

Dumond Bourie A, Potier J-B, Pinget M, Bouzakri K.

Non-alcoholic fatty liver disease (NAFLD), mainly characterized by fat accumulation in the liver, is a chronic hepatic disease with a worldwide prevalence of 25%, and notably present in 2/3 of the diabetic patients. At it evolves, NAFLD can progress to a more severe form, the non-alcoholic steatohepatitis (NASH) and in some patients the disease evolves to cirrhosis and hepatocellular carcinoma, which can require a liver transplantation. To date, no specific treatment for this chronic hepatic disease exists.

For several years, the importance of inter-organs communication has been highlighted in the case of diabetes and its related metabolic diseases, such as NAFLD. The CeeD and ILONOV focus mainly on the beneficial effect of the myokines , molecules secreted by the muscle during physical activities, on the different insulin-sensitive organs such as the pancreas, the liver and adipose tissue.

Through this review, our teams have summarized the existing literature to put a light on the role of different myokines on the physiopathology of NAFLD, and on their beneficial effect on different hallmarks of NAFLD and its complications, such as lipid accumulation, inflammation, fibrosis for example. Thus, this review highlights the potential therapeutic role that could have myokines in the treatment of non-alcoholic hepatic diseases.

Link to the paper: https://www.mdpi.com/2072-6643/15/7/1729

Collaboration with Emmanuelle Meugnier, the genomics platform manager of the CarMeN laboratory at Lyon-Sud hospital

Thu, 30 Mar 2023 09:31:17 GMT

Melissa Yepmo, PhD student at CeeD, focuses her research on the unique signature of circular RNA within human skeletal muscle and its impact on muscle and pancreatic islet metabolism. To develop her project, she had the opportunity to get the help of Emmanuelle Meugnier, the genomics platform manager of the CarMeN laboratory at Lyon-Sud hospital.

The pathologies of diabetes are complex and affect numerous organs such as the liver, pancreas and skeletal muscle. CircRNAs designate an emerging class of non-coding RNAs that is still very unexplored, but initial studies have recently shown that circRNAs are involved in the regulation of insulin secretion. Therefore, deregulation of this class of RNAs may lead to metabolic disorders in pancreatic β-cells and thus be involved in the pathogenesis of type 1 diabetes (T1DM) and type 2 diabetes (T2DM).

Our work with Emmanuelle Meugnier especially focuses on circRNA, by detecting them by qPCR with new protocols. We also sought to identify these circRNAs in skeletal muscles using high-throughput sequencing techniques. This work has enabled Mélissa Yepmo to expand herknowledge of genomics and to set up new protocols to improve circRNAs detection.

Société Francophone du Diabète (SFD) 2023 in Montpellier, FR

association@ceed-diabete.org (Claire MASALSKI) — Thu, 23 Mar 2023 08:16:15 GMT

March 21-23, 2023

The 2023 edition of the SFD congress, which took place in Montpellier, was an opportunity for Dr Allan LANGLOIS and Pr Michel Pinget to present CeeD's projects.

1 - Pr Michel Pinget with our latest epidemiological study, data was collected thanks to more than 12,000 anonymous screenings carried out between 2015 and 2021.

Written by Pr Pinget, it enlights health of subjects living in the Grand Est Region (France). Screenings involves a large population of unselected subjects, study focuses on non-diabetic adults, i.e. 8,354 people, to conclude that:

nearly 50% of the population studied is overweight or obese;
nearly 12% of subjects have unrecognized disturbed (suspicious or abnormal) blood sugar levels;
this prevalence significantly increases starting the age of 40 and/or for a Body Mass Index (BMI) greater than or equal to 25 kg/m².

2 - Dr Allan LANGLOIS with the projet "Peptide X, a promising inhibitor of MP001 protein which improves human pancreatic islet survival and function”.

Thus, our laboratory has identified for the first time that the MP001 protein represents a target of major interest for improving insulin secretion and the survival of human pancreatic islets. Finally, we have implemented a promising pharmacological strategy targeting MP001 to treat subjects with diabetes because this new molecule improves the functionality and survival of human pancreatic islets.

Thanks again to the SFD for making it possible to present these results and for the rich exchanges with experts in the field that resulted from this intervention. These will make it possible to deepen the investigations of the project.Nouveau paragraphe

Peptide X, un inhibiteur de la protéine MP001 prometteur pour améliorer la survie et la fonction des îlots pancréatiques humains

A. Langlois1, M. Kanzaki2, G. Bechtluft1, M. Pinget1 and K. Bouzakri1.

1. DIATECH, UMR 7294, Centre Européen d’Etude du Diabète, Université de Strasbourg, Boulevard René Leriche, 67200 Strasbourg, France.

2. Department of Biomedical Engineering, Graduate School of Biomedical Engineering, Tohoku University, 6-6-04-110 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi, JAPAN. 980-8579.

Introduction

Nous avons montré par protéomique que plusieurs protéines étaient régulées positivement dans les îlots pancréatiques humains lors d'une exposition à un milieu conditionné dérivé d'une culture de cellules musculaires squelettiques résistantes à l'insuline induite par incubation avec du TNF-α. Parmi celles-ci, nous avons identifié MP001. Nous avons démontré que MP001 est une protéine impliquée dans l'exocytose des granules d'insuline et que son inhibition par silencing améliore la survie et la fonction des îlots. L’objectif du projet était de développer une stratégie pharmacologique d'inhibition de MP001 et d'évaluer son effet sur la survie et la fonction d’îlots humains. Pour cela nous avons testé le Peptide X.

Matériels et méthodes

Des îlots pancréatiques humains furent incubés pendant 24h avec ou sans 0,1µM de Peptide X. Leur fonctionnalité a été évaluée avec un test de sécrétion d'insuline (GSIS). De plus, l'effet du peptide X sur la survie et la fonction des îlots a été étudié par Western blotting en ciblant les protéines AKT, PGC1α, Tbc1d1 et AS160.

Résultats

Le Peptide X potentialise la sécrétion d'insuline par rapport au contrôle (Peptide X: 16,7mM glucose = 4,35±0,52% versus 2,8mM glucose = 1,24±0,33% du contenu d’insuline total, p< 0,001; Contrôle: 16,7mM glucose = 3,30±0,39% versus 2,8mM glucose = 1,25±0,28% du contenu d’insuline total, p < 0,01; n=13). De plus, nous avons observé que le Peptide X augmentait significativement l’expression de protéines impliquées dans le trafic des vésicules d’insuline tel que AS160 (185±36% versus contrôle, p<0,05; n=9) et p-Tbc1d1 (180±39% versus contrôle, p<0,05; n=7). Enfin, le peptide X améliore la survie des îlots humains en augmentant l'activation de l'Akt (p-AKT/AKT: 180±47 % versus contrôle, p <0,001; n=7) et l’expression de PGC-1α (146±12% versus Contrôle, p<0,05; n=5).

Conclusion

Nous proposons que le Peptide X, en inhibant MP001, pourrait être une approche thérapeutique prometteuse pour les patients diabétiques.

New publication on circRNA and NAFLD

Wed, 02 Nov 2022 11:12:49 GMT

November 2, 2022

"Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications"

Yepmo M, Potier JB, Pinget M, Grabarz A, Bouzakri K, Dumond Bourie A.

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that affects 25% of the world's population. Characterized by an accumulation of fat in the liver, the onset of NAFLD is often linked to other metabolic pathologies such as diabetes or obesity. As the disease progresses, it can worsen into a more severe form, non-alcoholic steatohepatitis, or NASH. For some patients, the disease may progress to cirrhosis which could lead to liver transplantation, as no pharmacological treatment exists to date.

In recent years, advances in genomic research have identified a new and unique type of RNA, circular RNAs. The properties of these RNAs in many physiological and pathological contexts have been recently described and they possess pleiotropic properties due to their ability to regulate the expression of many genes and proteins throughout the organism. Through this review, our teams have synthesized the state of the art of the existing literature in order to highlight the impact of certain circular RNAs on the evolution of NAFLD. Thus, we brought a better understanding of the role, beneficial or deleterious, of these new RNAs on the various physiopathological aspects of NAFLD and NASH.

Link to the paper: https://pubmed.ncbi.nlm.nih.gov/36407314/

Société Française d’Endocrinologie (SFE) 2022 in Nantes, FR

association@ceed-diabete.org (Claire MASALSKI) — Wed, 12 Oct 2022 07:21:21 GMT

12-15 october 2022

CeeD participated to the French Society of Endocrinology congress held from the 12th to the 15th of October 2022 at the Cité Nantes Congress Centre.

Dr Aurore Dumond presented a poster untitled “Prevention and treatment of NASH by myokines”

on CeeD work on the treatment of non-alcoholic fatty liver diseases linked to diabetes, such as NASH. This work is focussing mainly on the myokines secreted by the skeletal muscle and their potential beneficial role on different aspect of NASH such as insulin resistance and lipid accumulation in the liver.

Abstract :

Prévention et traitement de la NASH par des myokines

Aurore Dumond, Jean-Baptiste Potier, Achilleas Fardellas, Myriam Aouadi et Karim Bouzakri

Objectifs : Les myokines, notamment la myokine X (MyoX), ont un rôle majeur dans la communication inter-organes, aspect crucial des maladies métaboliques comme le diabète de type-2 (DT2). La stéatohépatite non-alcoolique (NASH) étant étroitement liée au DT2, notre but est de déterminer si la MyoX pourrait être une thérapie de la NASH. Pour cela, des sphéroïdes d’hépatocytes humains primaires (sPHH), modèle in-vitro d’excellence de la physiopathologie du foie, sont utilisés.

Matériels et Méthodes : Les sPHH sont ensemencés dans du milieu contrôle ou de syndrome métabolique (MetS), traités à différentes concentrations de MyoX, puis challengés à l’insuline. Les effets de la MyoX sur les protéines impliquées dans le métabolisme du glucose et des lipides et induisant la NASH sont déterminés par Western Blot et l’accumulation de triglycérides dans les sphéroïdes est observée par une coloration au Nile Red.

Résultats : En condition contrôle, la combinaison d’insuline avec de la MyoX améliore la réponse à l’insuline dans les hépatocytes : augmentation nette de la phosphorylation d’AKT et AS160 et de l’expression de GLUT2 et inhibition de la phosphorylation d’ERK1/2. En condition de MetS, une diminution de l’accumulation des triglycérides liée à celle de la phosphorylation de SREBP1c est observée à faible dose de MyoX.

Discussion : Nos résultats suggèrent que la MyoX, améliorant les effets de l’insuline sur les sPHH en condition contrôle, pourrait avoir un rôle préventif sur la NASH et, diminuant l’accumulation de triglycérides dans les sPHH en condition MetS, pourrait être une thérapie intéressante pour la NASH.

European Association for the Study of Diabetes (EASD) 2022 in Stockholm, SE

association@ceed-diabete.org (Claire MASALSKI) — Mon, 19 Sep 2022 07:20:30 GMT

September 19-23, 2022

Dr Allan LANGLOIS presented a project from CeeD entitled "Peptide X, a promising inhibitor of MP001 protein which improves human pancreatic islet survival and function”

The objective of this study conducted in collaboration with Pr Makoto KANZAKI, from Tohoku University in Japan, was to identify a new therapeutic target to treat patients with diabetes and to develop a pharmacological approach. Thus, our laboratory has identified for the first time that the MP001 protein represents a target of major interest for improving insulin secretion and the survival of human pancreatic islets. Finally, we have implemented a promising pharmacological strategy targeting MP001 to treat subjects with diabetes because this new molecule improves the functionality and survival of human pancreatic islets.

This major international congress in the field of diabetology was an opportunity to listen to numerous high-level works and to meet renowned scientists. Furthermore, it was a real opportunity to be able to present my results and discuss them with these experts.

Abstract :

Peptide X, a promising inhibitor of MP001 protein which improves human pancreatic islet survival and function

A. Langlois1, M. Kanzaki2, G. Bechtluft1, M. Pinget1 and K. Bouzakri1.

1. DIATECH, UMR 7294, Centre Européen d’Etude du Diabète, Université de Strasbourg, Boulevard René Leriche, 67200 Strasbourg, France.

2. Department of Biomedical Engineering, Graduate School of Biomedical Engineering, Tohoku University, 6-6-04-110 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi, JAPAN. 980-8579.

Background and aims:

Previously, our team identified by proteomics that several proteins are up-regulated in human pancreatic islets upon exposure with conditioned medium derived from insulin-resistant skeletal muscle cell culture induced by incubation with TNF-α. Among them, the MP001 protein which has been identified as being specific for the β-cell. Recently, we demonstrated that MP001 is a key protein involved in insulin granule exocytosis via an impact on the dynamics of actin filaments and cellular remodeling of β-cells. Moreover, its inhibition using siRNA technology improved human pancreatic islet survival and function. The aim of this project was to developed a pharmacological strategy of MP001 inhibition and to evaluate it effect on human islet survival and function. For that we have tested the Peptide X.

Materials and methods:

Studies were carried out on human pancreatic islet. These were incubated for 24h in presence of Peptide X 0.1, 1 or 10µM versus its Peptide control. Islet functionality was assessed using glucose stimulation insulin secretion test. Data were expressed in percentage toward total insulin content. Moreover, the effect of Peptide X on islet survival and function was studied using western blotting targeting Akt, p-Akt, NFκBp65, p-NFκBp65, PGC1α, IRS1, p-IRS1, IRS2, p-IRS2, Tbc1d1, p-Tbc1d1 and AS160. Protein expression was reported as a percentage versus Peptide control. Statistics were performed using non parametric test (Mann Whitney) for molecular study and ordinary one-way ANOVA followed to multiple comparison test for functionality evaluation. Data were reported as mean ± SEM for the indicated number of replicates and a p value of <0.05 was considered statistically significant.

Results:

Firstly, we showed that Peptide X potentiates insulin secretion from 0.1µM in comparison to control with no improvement for higher concentrations (Peptide X 0.1µM 16.7mM glucose = 4.35±0.52%, Peptide X 0.1µM 2.8mM glucose = 1.24±0.33%, p< 0.001 n=13 versus Peptide control 0.1µM 16.7mM glucose = 3.30±0.39%, Peptide X 0.1µM 2.8mM glucose = 1.25±0.28%, p< 0.01 n=13). Thus, for the molecular study we used 0.1µM. Secondly, proteomic demonstrated that Peptide X improves human islet survival increasing Akt activation (p-AKT: 206±67% versus control, p<0.001, n=7), NFkBp65 (139±28% versus control, n=9) and PGC-1α expressions (146±10% versus control, p<0.01, n=5). Finally, Peptide X has a positive action on islet function up-regulating proteins involved in insulin molecular pathway as IRS1 (283±83% versus control, p<0.001, n=10), p-IRS2 (179±42% versus control, p<0.05, n=9), p-Tbc1d1(179±39% versus control, p<0.05, n=7) and AS160 (185±36% versus control, p<0.05, n=9).

Conclusions:

Our study has demonstrated for the first time that Peptide X, inhibiting MP001, improves human pancreatic islet survival and function. Consequently, based on our data, we propose that Peptide X could be a promising therapeutic approach for diabetic patients.

International Liver Congress 2022 by EASL in London, GB

association@ceed-diabete.org (Claire MASALSKI) — Wed, 22 Jun 2022 07:25:46 GMT

June 22-26, 2022

The CeeD was present at the International Liver Congress 2022 organised by the European Association for the Study of Liver (EASL) in London.
Dr Aurore Dumond and Jean-Baptiste Potier, PhD student, from CeeD, presented a poster about " Skeletal muscle-derived myokine affects insulin sensitivity and lipogenesis in a human hepatocyte spheroid model ” on their work on the non-alcoholic fatty liver diseases, such as NASH, linked to diabetes.
This work is carried out in collaboration with Prof. Myriam Aouadi and Achilleas Fardellas from the Karolinska Institutet in Sweden.

Société Francophone du Diabète (SFD) 2022 in Nice, FR

association@ceed-diabete.org (Claire MASALSKI) — Tue, 22 Mar 2022 08:26:22 GMT

March 22-25, 2022

CeeD was in Nice for the congress of the Francophone Diabetes Society!

Our centre was represented by Dr Karim Bouzakri, head of our laboratory, Dr Allan Langlois and Dr Aurore Dumond, both Project managers at CeeD.

They presented our poster: "La Myokine X, myokine dérivée du triceps, protège les cellules bêta pancréatiques contre l'inflammation chronique" meaning "Myokine X, a triceps-derived myokine, protects pancreatic beta cells against chronic inflammation".

Collaboration with the Karolinska Institutet - 2022

Mon, 21 Feb 2022 10:42:25 GMT

Jean-Baptiste Potier, PhD student at CeeD and ILONOV, had the opportunity to travel to Stockholm in Sweden, in order to learn a new scientific technic for his PhD project at the Karolinska Institutet.

His PhD project focuses on the study of the crosstalk between skeletal muscle and the liver, in the context of metabolic diseases and more precisely, the impact of myokines, proteins that are secreted by skeletal muscle during physical activity, and their potential to prevent metabolic related liver diseases. The main diseases he focusses on are non-alcoholic fatty liver diseases (NAFLD) and its evolution, non-alcoholic steatohepatitis (NASH). These two diseases are caused by an abnormal accumulation of fat inside the hepatocytes, the main cell type of the liver. This phenomenon, called steatosis, can negatively affect the metabolism of liver and can evolve toward inflammation and fibrosis. The final stage of the affection, for which there is yet no approved medication except liver transplantation, is cirrhosis.

Between January and February 2022, he had the chance to be welcomed by a research group from the Karolinska Institutet, a prestigious and recognized research institution. The aim of the visit was to learn a 3-dimensional cell culture model, called spheroids, using human liver hepatocytes that allow studying the mechanism and new potential treatment for metabolic liver diseases, such as hepatic steatosis and insulin resistance. Due to its 3D shape, this recent model closely reproduces the in vivo environment and cell communication.

Eurodia Meeting 2019 - Review on the third edition of our scientific and medical congress

association@ceed-diabete.org (Claire MASALSKI) — Thu, 21 Nov 2019 08:25:01 GMT

November 21-22, 2019

Call for abstracts

This year again, CeeD launched a call for abstracts to favour the promotion of original research work (unpublished) and the presentation of new talents.

Around 15 abstracts have been selected for a poster communication during Eurodia Meeting and two prices have been attributed to the best of them by the jury:

Alexis Forterre for his work on “Use of targeted mRNA-loaded Extracellular Vesicles (EVs) for the specific delivery to cells and tissue”
Laura Reininger for her work on “Insulin-resistance induced TNF-alpha in C2C12 increase the release of exosome-like vesicles which affect insulin of pancreatic beta-cells”

Synthesis on this third edition

Secretary: Dr Allan Langlois and Dr Alexis Forterre

“Pursuing the study of human physiology and physiopathology of diabetes to bring innovative therapeutics solutions” is one of the numerous recommendations proposed by Pr Michel Pinget (professor emeritus of Strasbourg university and President of CeeD) during the third Eurodia Meeting co-organized by himself and Dr Karim Bouzakri (director of CeeD Research Laboratory). This congress was led the 21st and 22nd of November 2019 at the Hôtel du Département of Strasbourg. It reunited around 200 participants from the scientific community (researchers) and the medical profession (doctors and clinicians) coming from different regions of France, but also from Switzerland, Belgium, Italy, Sweden and Japan!

Diabetes is the first pandemic, which origin is not linked to pathogenic agents (bacterium, viruses…) but to the direct impact of Human! Indeed, it is clearly proven that the environmental and societal factors play an important role in the apparition and development of the disease. One of its plagues is obesity.

To date, we count more than 463 million of diabetics worldwide (including 4.5 million in France) for a cost of 715 milliards of dollars (19 milliards for France). The projections are not encouraging: 1 milliard of diabetics for a health cost of 1000 milliards of dollars are scheduled for 2040 in the World. Due to this dramatic report, a fundamental question was asked to Pr Michel Pinget: “Can the unacceptable be avoided?”. That is around this question that was organized the all congress.

This question firstly highlighted that it is crucial to rethink the whole health system and to favour an innovative and complementary form of inter-professional work in the future to ensure a better health management of the diabetic patient. This will need the creation of new professions, such as IPA (infirmières en pratique avancée for advanced practice nurses), of new tools of prevention, diagnostic and screening such as telemedicine (ex: PeDi-DIAB for the follow-up of the diabetic foot held by Pr L. Kessler). This will enable the access, efficacy and quality of healthcare provided to the patients and to facilitate the exchange between the different care professions. Those innovative improvements will enable a better patients’ management and a better care organisation while relieving the work overload of doctors.

Secondly, it is with the improvement of the knowledge of human physiology and of the physiopathology of diabetes that we will be able to propose new therapeutics solutions to patients and so “avoid the unacceptable”.

Where do we stand today?

The well-established fact is that the common cause of all diabetes is the decrease in the number of functional insulin cells. It is, thus, required to protect the pancreatic islet or to replace it. A fundamental discover from the last years is the existence of a crosstalk dialog between the different organs playing a major role in insulin secretion, in the protection of insulin cells and in the regulation of glycaemia. These works directed by Dr K. Bouzakri (muscle/pancreas) and the Pr H. Katagiri (nervous system/ pancreas) insist on the important role of the different organs (muscle, pancreas, liver, brain…) in the regulation of insulin secretion. Other teams demonstrated the existence of secreted messengers by these organs, like the myokines (Dr K. Bouzakri) or also the secreted vesicles by the cells of the organism (exosomes by Pr R. Regazzi). Finally, Pr M. Kansaki completed these current knowledge with a presentation on the insulin secretion mechanisms.

In addition, the biomedical research on the physiopathology of diabetes have also increased significantly and help on the comprehension of the disease. Indeed, Dr M. Aouadi presented her work on the implication of inflammatory cells in the liver, which favour the development of insulin resistance and of type-2 diabetes (T2D). Those studies were completed by Pr M. Doffoel and Pr B. Staels on one of T2D complications, NASH (non-alcoholic steatohepatitis). This disease, maintained by insulin-resistance, is responsible of cirrhosis that can lead to cancers apparition, but also to cardiovascular diseases. Finally, Pr M. Buysschaert indicated that the diabetic patient might be more prone to the development of parodontal diseases. These diseases predispose to (pre-) diabetes and contribute to the chronic glycaemic imbalance.

What about the different therapeutic strategies currently proposed?

The medecines used to date do not directly target the insulin cells but all the organs involved in the glycaemic regulation (liver, intestine…) and the complications linked to diabetes (cardiovascular…). This drugs panel should be enriched in a foreseeable future thanks to new discovery. Dr C. Caussy has highly insisted on the respect of hygiene-dietetic measures (a varied and balanced diet with regular physical activity) as a treatment for the diabetic patient.

Cellular therapy is also a used strategy (islets transplantation) to treat type-1 diabetes, with an efficacy of around 10 years on the glycaemia regulation and the decrease of severe hypoglycaemia. However, this strategy’s issue is the necessity to get 2 to 3 pancreas to treat only one patient . As highlighted by Dr T. Hubert, it is established that to solve this issue it is essential to have a pancreas from a donor of high quality, but also to improve the technics of collection, preservation of the organ as well as the preparation of islets before the transplantation. In this sense, it has been proposed the use of support matrices (Dr E. Maillard) or the use of physiological molecules secreted by the muscle (Dr K. Bouzakri and Pr M. Pinget). Furthermore, to overcome the difficulty to obtain pancreatic islets, it is also considered to replace the deficient insulin cells by stem cells or by a bioartificial pancreas such as Viacyte® (Pr L. Piemonti). Finally, Pr K. Furuyama proposed the reprogrammation of diverse cells in insulin cells to regenerate the deficient ones.

To conclude, the multidisciplinary of the actors involved daily in the fight against diabetes (researchers and doctors of international renown) will enable the development of tomorrow’s strategies for a better management and an efficient treatment of the diabetic patient.

Travel grant Japan JDS EFSD from 01/2018 to 04/2018

association@ceed-diabete.org (Claire MASALSKI) — Wed, 03 Jan 2018 10:18:58 GMT

“Role of MP001 protein in β-cell function and survival in healthy and diabetic patients.”

Dr Allan Langlois, project manager at CeeD, had the opportunity to be welcomed at Tohoku University in Japan by Pr Makoto Kanzaki, who developed impressive technic based on single molecule imaging with Quantum dot fluorescent nanocrystals. This method is able to dissect intracellular vehicle trafficking processes into discrete and experimental traceable steps.

Obesity and type 2 diabetes mellitus (T2D) are characterized by an overlapping phenotype of insulin resistance with a relative deficiency in insulin secretion underlying hyperglycemia in T2D. Our research team have hypothesized that a conversation between skeletal muscles of different insulin sensitivity and β-cells exists. Our results further suggest that the nature of communication between skeletal muscles and β-cells is dependent upon fiber composition as well as insulin sensitivity. We have identified by Six-plex TMT labeling that several proteins are regulated in human islets exposed to T2D skeletal muscle cells condition medium (T2D CM). MP001 protein was found to be increased in human islets cells exposed to T2D CM. Interestingly, the regulation of MP001 expression and phosphorylation as well as its function in β-cells is unknown. MP001 is localized to the plasma membrane and is an actin filament crosslinking protein. MP001 phosphorylation inhibits its association with actin and with the plasma membrane, leading to its presence in the cytoplasm. Our preliminary data showed an impact of MP001 in insulin secretion either in rat or Human β-cells. Nevertheless, the precise underlying mechanisms needed to be explored in control and diabetic conditions. Thus, the main goal of this collaborative project with Pr Makoto Kanzaki was to provide further insight into MP001 impact on insulin granule trafficking and its interaction with actin in human islets single cells from control and T2D donors.

By obtaining the “Travel grant from JDS EFSD”, Dr Allan LANGLOIS came to Kanzaki’s laboratory to explore in details actin dynamic and insulin granule trafficking in single cells exposed to different conditions (control versus siMP001) using single molecule imaging with Quantum dot fluorescent nanocrystals.

Eurodia Meeting 2017 - Review on the 2nd edition of our scientific and medical congress

association@ceed-diabete.org (Claire MASALSKI) — Thu, 09 Nov 2017 08:24:12 GMT

November 9-10, 2017

New in 2017: Call for abstracts

This year, CeeD launched a call for abstracts to favour the promotion of original research work (unpublished) and the presentation of new talents. The twentyish selected abstracts have benefited of a poster communication during the Eurodia Meeting and two prices were attributed to the best of them:

Caroline Aroux for her work on “Analysis of the adhesion-mediated control of insulin secretion in response to glucose and autocrine insulin/IGF2-signaling in pancreatic β-cells”
Florian Dingreville for his work on “ Glucotoxicity disrupt mitochondrial network and insulin secretion in pancreatic bêta cell” Nouveau paragraphe

Synthesis on the second congress

Secretary: Julien CHERFAN

Created on the initiative of CeeD in a translational dynamic, Eurodia meeting congress offers to the scientific community and to the medical profession a perfect opportunity to share the latest advances in diabetology. While we note that the diabetes pandemics far exceeds the initial projections, it becomes more than necessary that researchers and clinicians work and meet the challenges induced by the diabetes together.

Type-1 diabetes, in a constant increase, is a challenge to solve both by the treatment and by the management of the patient, for those patients who are going to live with this chronic disease all their life.

Professor Bougnères, paediatrician at Saint Vincent de Paul hospital and type-1 diabetes specialist in the children, wants with his team to determine what are the mechanisms inducing the development of type-1 diabetes , a question still unanswered. For that, they have studied “real” twins and they highlighted that genetics cannot explain everything. Indeed, by having exactly the same genetic code, one of the twins can develop diabetes but not the other one. Thus, an important environmental component has to be taken into account in the development of the disease, notably at the microbial level. By analysing patients’ data, Pr Bougnères was able to identify some markers: influenza-like illness might increase the probability to develop diabetes, while varicella and childhood diarrhea would have a protective role.

Researcher at CeeD, based in Strasbourg and at the initiative of this congress, Dr Karim Bouzakri presented the status of his research on the effect of sport in the prevention and the cure of type-2 diabetes . He discovered that muscle activity induces the secretion of myokines, molecules transported by the blood and enabled to “talk” to other organs, notably to the pancreas. One of the myokine has particularly been isolated as it is presenting a very interesting profile due to its capacity to protect the pancreas, while increasing insulin secretion. Dr Bouzakri studies at the cellular level the beneficial action of sport activity. This benefit seems to be double: on one part the muscle consumes the blood glucose and on the other part, it protects from diabetes development thanks to its myokines secretion.

Dr Said Bekka, specialist of the diabetes pathology and editor of the journal “Diabète et Obésité” (Diabetes and Obesity), decided to show the example to his patients by participating with them in extreme sports. For him, the type-1 diabetic patient is comparable to a high-level athlete: he should adapt his treatment, be disciplined and being able to improvise. Knowing this comparison, to fight against the fatalism accompanying the heavy management of the disease, different sports achievements have been achieved by Dr Bekka and his patients: New-York Marathon, Kilimandjaro climbing, swimming across the English Channel, the North Pole… Some patients, previously pessimistic are now more combative and reduce by half their insulin consumption.

Langerhans islets physiology, islets being at the centre of the disease and in interaction with other organs, continues to unveil its mysteries.

Diabetic pathology consists in a metabolic imbalance; it is on that aspect that Pr Wollheim focussed his work. Currently Professor Emeritus at the cellular physiology and metabolism department of the University Medical Centre of Geneva, Pr Wollheim presented his last discoveries on the mitochondria, motor of the cell, which transform sugar to energy. With his team, he highlighted that glucose overabundance can cause the mitochondria to “overheat”. That energy imbalance induces severe consequences on the cell, notably on pancreatic cells. Those results explain in part the long-term decline in insulin production and the onset of type-2 diabetes.

What is the link between child malnutrition and adult type-2 diabetes? That is the question that tries to answer Pr Van Obberghen from the Molecular Biology and Biochemistry department of the Medical Faculty of Nice. He managed to associate a dietary deficiency in pregnant women, with implications in the fetal development. That dietary deficiency can predispose the adult to type-2 diabetes. He proves, in animals, that a low protein diet for pregnant female led to a decrease of pancreatic islets number and by consequence of insulin secretion.

The Human digestive tract is an extremely complex machinery where can be found more than 10 million of microbial genes produced by more than 1500 different bacterium species. Dr Burcelin, director of the team “Intestinal risk factors for metabolic diseases” at the hospital Rangueil of Toulouse, took an interest into that ecosystem in diabetic and obese patients. In that optic, he used a mathematical method able to compare the bacterial profile of diabetic, obese et healthy patients. He concluded that healthy patients have a larger bacterial diversity. More surprising, by implanting bacterium from an obese mouse to a healthy one, the last one also becomes prone to overweight.

A round table on The future of diabetic patients through technological innovation enabled to the guests and to the participants to confront their ideas on the issues of the future that could induce real scientific and medical progress.

Pr Renard teaches endocrinology, diabetology and metabolism at the Medical Faculty of Montpellier. He works on the pump/sensor coupling of the artificial pancreas , to improve the release of insulin during the day. Indeed, it is for the moment difficult to predict the glycaemic variations that can occur and the risks to go out the norm (0.7g/L – 1.8g/L) are elevated. To increase sensor performances, Pr Renard propose a system enabling the diabetic patient to announce to its device the food intake and so enabling the pump to anticipate the insulin injections. That system ables the reduction of hypoglycaemia events and a better quality of life for the diabetic patient.

At the Medical Faculty of Lille, Pr Pattou teaches surgery in the endocrinology department. Since 10 years, he is interested in pancreatic islets transplantation in the liver , technic, which aim is to limit severe hypoglycaemia by injecting Human islets directly in the liver (and not in the pancreas). This approach proved its efficacy and certain transplanted patients were able to live years without any insulin injections.

Dr Séverine Sigrist, president of Defymed start-up, CeeD spin-off, presented her principal project: Mailpan bioartificial pancreas . This device is presented in the form of a small flat pocket that is placed surgically under the skin at the abdominal level. The diabetic patient body will vascularize the side walls and enable the nutrients exchanges with the organism. The MAILPAN semi-permeable membrane will blocks the immune molecules but enables the insulin release into the blood circulation. Thus, thanks to this device, we will be able to transplant a functional pancreas in diabetic patients, without the use of anti-rejection treatments and without their toxicity. This approach will offer, at term, a real solution to type-1 diabetic patients.

A state-of-the-art on the cardiovascular risks related to diabetes (current treatments, novel therapeutics and eventual associated risks) was organized to improve the management of patients thanks to the current tools.

Pr Pierre-Henry Ducluzeau, professor in Human Nutrition at the University Hospital centre of Tour, contributed his expertise on the role of statin in the media and the medical reality following a recent controversy over the use of statins, their potential inefficiency and their adverse effects. However, experts seem to agree on their beneficial role and their capacity to decrease LDL in the blood (bad cholesterol). Furthermore, a discontinuation of the statins treatment in high risks patients is linked to an increase of cardio-vascular mortality.

The links between diabetes and cancers were presented during Eurodia meeting to rethink the management of diabetic patients notably through cancers screening.

β cells present in the pancreas are very specific compared to other human cells, which explains in part the high aggressivity and mortality of pancreatic cancers. Highlighting this finding, Pr Charles Thivolet, professor and doctor at the CHU of Lyon, drew the parallel between diabetes and pancreatic cancer . During his research, it clearly appears that the common denominator of these two pathologies is obesity. Cancerous pancreas and type-2 diabetic pancreas are infiltrated by adipocytes (cell that store fat), which have an important influence both on cancer apparition and on diabetes. Indeed, cancer is generally identified in the three years following type-2 diabetes diagnostic.

Pr Mathelin, currently responsible of the Senology Unit of the CHRU of Strasbourg and Professor at the Medecine Faculty, is interested in the relationship between diabetes and cancer, but more particularly on breast cancer. Her work demonstrates a higher incidence and a mortality of breast cancer in diabetic women. This could be explained by common risks factors: overweight and sedentary lifestyle. This prevalence is still badly known by doctors. To solve this issue, Pr Mathelin propose a better senology follow-up for type-2 diabetic women of more than 50 years old, with mammographic screening every 2 years.

The last round table on Virtual Medecine, real diagnostic and clinical management enables to close this interesting congress rich in speakers and content.

Big data in medicine is composed of huge numeric data bank concerning patients, their pathologies and the efficacy of treatments. To draw conclusions about this mass of information, informaticians are getting involved by the specialists. It is in this perspectives that Karl Neurberger, graduated of the HEC Polytechnic School and Data Scientist at Quantmetry, launches the project “Senometry”. This project’s aim is to analyse the data of more than 10000 patients with breast cancer. The cross analysis of these data will give some answers to unresolved questions and will enable to identify unexpected correlations.

Pr John Pickup, graduated from Oxford, works at the Medical Faculty of King’s Colleges in London, in a department specialized in diabetes and metabolism. Pr Pickup has focused his presentation on the perspectives given by the collected data from diabetic patients.

Pr Guy Rutter, at the head of the cellular and genomic function department of Imperial College in London, is considered as a reference in diabetes domain and his works are recognized in the entire world. He, thus, presented how high levels of sugar and fatty acids reduce insulin secretion. That nutrients’ abundance induces a cellular toxicity and modify the communications between pancreatic β cells. Ultimately, this context is extremely deleterious and induces a vicious circle in, which high glycaemia decreases insulin secretion, which induces the increase of glycaemia.

To conclude this congress, Pr Reach, teacher in endocrinology at Paris 13 University, offered a reflexion on the relationship between patients-doctors in diabetic therapy. Due to the triumph of medicine based on scientific evidence (EBM - Evidence Based Medicine), he questioned the lack of compliance of diabetic patients and of patients in general. Modern medicine is based on a triangulation: science data, doctor experience and patients’ preferences. To be able to draw a conclusion from a study, it is necessary to have a large panel of information gathered from a high number of anonymous persons and this, to obtain a scientific objectivity based on the interpretation of selective data. However, the relationship between the doctor and his patients is based on subjectivity. It’s a dialog between two “complex minds” that have to be considered.

Conclusion:

This second edition of Eurodia Meeting highlights the different aspects of this complex disease and notably the close relationship linking diabetes to cancer. A main idea emerges from these two days of conferences: the place of obesity as a major risk for the apparition of diabetes but also of cancer, which reinforces again the importance of a healthy lifestyle with regular physical activity.

The European Union distinguishes CeeD through Maria Sklodowska-Curie Excellence Grant

association@ceed-diabete.org (Claire MASALSKI) — Fri, 22 Sep 2017 07:19:32 GMT

European Program for HORIZON Research Innovation 2020

CeeD anounces the obtention of the European grant “Marie Sklodowska-Curie” for its laboratory. This grant will allow the coming of a high level researcher and thus accelerate CeeD research work on the understanding of diabetes’ cellular mechanisms and more particularly on the link between physical exercise and diabetes.

After a thorough evaluation of “Exodia” file presented by CeeD, the European Union awarded it the « Individual fellowships - Actions Marie Skłodowska-Curie » grant, Grant Agreement N°753670, to contribute to the development of its new research program Exodia. Amounting to almost 200 000 €, this grant is intended mainly to the recruitment of a high level researcher coming from an international laboratory. From the “Scientific Excellence” part of the “Horizon” Research Innovation Programme 2020, that grant is allocated by a jury of international experts according to four criteria: the scientific quality of the project, the excellence of the host institute and of the candidate-researcher but also on the potential impact in favour of the European competitivity.

In this context, CeeD will host, beginning of 2018, Doctor Maria Luisa Mizgier from the Pontifical University Catholic of Santiago de Chile. Graduate of a PhD with very honourable mention, and after a career path carried out within prestigious laboratories, notably in Paris, Geneva but also Harvard, this French-Chilean researcher will join CeeD for an initial period of 2 years to develop the Exodia project.

Exodia, at the heart of a major public health issue

Diabetes results from an insufficient or misuse of insulin, hormone produced by the pancreas. This chronic disease develops in response to several factors, of which sedentary status (In the case of type-2 diabetes, which represents 90% of diabetes cases worldwide according to OMS/WHO). On the contrary, an adapted physical activity is described as one of the most efficient means of prevention and treatment for all diabetes.

Pioneer in the field, the Dr Karim Bouzakri, CeeD Reasearch Director, having himself been distinguished with Marie Sklodowska-Curie Grant, had updated and proved the existence of a real communication between the muscles and the pancreas. Those research work are now one of the main research axis of CeeD:

“ Crosstalk communication between the muscles and the pancreas ”.

Thanks to Exodia, CeeD will now be able to accelerate its research and:

decipher the communication mechanisms between the muscles and the pancreas at a cellular level to explain the benefits of physical exercises on diabetes and on its prevention;
ultimately, rethinking the therapies through physical exercise and develop innovative drug solutions against diabetes miming the effects of physical activity in a pharmacological manner.

CeeD's research, a growing international influence

Exodia project is part of a collaboration strategy initiated by CeeD with different European and worldwide laboratories of excellence working around its thematic “Crosstalk communication between the muscles and the pancreas”. Among its partner: Tokohu University (Sendai, Japan), London Imperial College, CarMeN institute (Lyon, france), the German Diabetes Center (Düsseldorf, Germany), the Center of Inflammation and Metabolism (Copenhagen, Denmark) or also Lausanne University (Switzerland).

Strengthening CeeD direction more than ever turned to international, this grant of excellence will also help to promote inter-laboratories mobility and technics sharing in favour of the CeeD research work.

At time when global diabetes growth projections remain extremely worrying, and given its dramatic impact on population health and the economic weight of the disease, the CeeD research contributes to fight against this global pandemic.

For the Professor Michel Pinget, founding president of CeeD and professor emeritus of Strasbourg University:

“This consequent financial engagement highlights the trust and the interest of the European commission to our team and to the research carried out in our laboratory.

Diabetes turns out to be a more complex disease compared to what the scientific community believed. Thus, eventhough the pancreas is at the heart of the disease, it is not the only organ involved. It interacts with different organs through signals ant it is through these signals that we will cure diabetes. Exodia project therefore fits perfectly to this new way of thinking about this disease. And its financing will participate to give to our researchers the necessary means to pursue their work and to transform the research to concrete therapeutics for the patients, even in prevention!”

Diabetes pandem ic, worrying figures

- While it did concern around 108 million of people worldwide (800 000 in France) in 1980, diabetes affects today more than 420 million of persons in the world (around 5 million in France). Not forgetting the diabetic persons non-diagnosed, which represent among 800 000 in France, including around 180 000 in Alsace: in practice, 1 adult out of 10 is concerned by diabetes, or will be in a foreseeable future. And among those chronic diseases, the specialists plan an increase of about 12% of diabetes cases between 2015 and 2020…

- The real consequences of diabetes and its complications are still poorly known or misunderstood. Yet beyond the disease itself, the diabetes exposes its patients to severe complications (amputation, blindness, end-stage renal failure, myocardial infarction or stroke…)

- Every 6 seconds, 1 person dies of diabetes in the world:

According to OMS, diabetes is the third factor of early mortality in the world, after blood pressure and smoking.

- The cost of diabetes for the society naturally reflects the severity of this chronic disease: it represents 5 to 20% of the health budget in developed countries (12,5% in average).

EuroDia meeting 2016 - β cell, From Bench to Bedside

Mon, 14 Nov 2016 14:16:32 GMT

November 4, 2016

Organised on the occasion of the 25 ^th birthday of CeeD, the first edition of EuroDia Meeting brought in Strasbourg a panel of experts around pancreatic β cells subject. In the interest of putting the research in a strategy of a concrete application for the patients, the conferences were held in three parts: from fundamental to the clinic without forgetting the preclinical part. This 360° vision provided an overview on the future of type-2 diabetes prevention and treatment, but also an inventory of islet transplantation in type-1 diabetes.

1/ Fundamental approach

Professor at Harvard University (Boston, USA), Rohit N. Kulkarni presented his work on the comprehension of cellular mechanisms that could be responsible of a restoration of β-cells number and so of the glycaemia. It is important to remind that in the diabetic patient, the number of β-cells (insulin secretion cells) highly decreases during the disease. For the first time, thanks to liver-produced growth factors, his team was able to induce the replication of those cells, in the aim to restore insulin production.

Research director at INSERM, working at the Institut de Génétique Biologique Moléculaire et Cellulaires (IGBMC) in Strasbourg, Gérard Gradwohl, also attempts to replace the destroyed β cells during diabetes. For that, with his team, he is dealing with the comprehension of how the pancreatic cell differentiation and maturation is held in the mice during the embryonic stage. The final aim is to transform stem cells into functional β cells to then transplant the patient.

To conclude on this fundamental session, Roméo Ricci, professor at the Medical Faculty of Strasbourg , also officiating at the IGBMC, presented his work not dealing with the cell multiplication but with their protection during the disease. With his team, he discovered that, in an nutrients-rich environment, β cells have a paradoxical tendency to evolve toward autophagy (digestion of the cell by itself). That cellular mechanism occurs generally in a period of food deficiency, however, due to a poorly known specificity of the β cell, the contrary is observed. This reinforces again the negative impact of a rich diet on the evolution of the disease.

2/ Preclinical approach

Professor at the University of Dusseldorf (Germany), Eckhard Lammert is interested in the cellular receptors enabled to increase insulin secretion. For that, he tested with success the effect of a cough medicine, the Dextrometorphan. With his team’s help, he demonstrated that this medicine induces a decrease of glycaemia in type-2 diabetic patients treated with Metformin, and this thanks to the blockade of some receptors.

Karim Bouzakri, research responsible at CeeD, has next presented his work, which objectives are to provide a cellular explanation to the beneficial aspects of physical activity on the disease. He, thus, highlighted that the physical activity of certain muscles has a protective effect on the β cells through myokines, molecules produced by the muscles themselves. It is a real dialogue occurring between the muscles and the pancreas and its comprehension will enable in the next years to rethink the therapies for the diabetic patients, not only through the sport, but also thanks to innovative molecules that could be developed from these myokines.

Β cell transplantation is a real hope for type-1 diabetic patients, but available cells are rare (missing donors). To solve this issue, Séverine Sigrist, research responsible at CeeD and CEO/CSO of Defymed spin-off , manages a very ambitious research program (by CeeD) for the development of a bio-artificial pancreas prototype (MAILPAN), but also for the preparation of its marketing by the realization of preclinical lots for the first tests in human (within Defymed). The cell availability, their long-term viability after transplantation and the rejection’s risk by the receiver are the major challenges to the large-scale development of islet transplantation. With MAILPAN®, the cells are confined in a pocket, which only let the nutrients pass and protects from the rejection of the transplantation. This method enables to avoid the use of immunosuppressive treatments and the devastating adverse effects that they cause.

3/ Clinical approach

Clinical Lecturer at Oxford University (United Kingdom), Ioannis Spiliotis presented the English public health program related to the pancreatic islet transplantation. The major challenge to transplantation is the great inequality between the number of candidates (huge) and the available organs (very rare). The solution found is the establishment of an organ distribution centre, able to choose the best receiver based on their profile. This centre is also responsible for the patients’ follow-up after the surgery and to gather the medical information in order to carry out the most judicious transplantation and, thus, to optimize the chances of success.

The scientific conferences were concluded by the intervention of Laurence Kessler, Professor of the University and doctor at University Hospital of Strasbourg (CHU Strasbourg) , who presented the French experience on transplantation and reported the first randomised study comparing transplantation to the other modes of intensified insulin therapy. She emphasizes that the objective is no more the look for an insulin-independence, which needs 3 donors, but to get a glycaemic stabilization, which could be obtained with less transplanted cells, and so less donors. Her position is similar to that of her English colleague. She also highlights the pilot experience carried out by the pneumology and diabetology teams of Strasbourg, on the islet transplantation in subject with mucoviscidosis and benefiting from a lung transplant.

Conclusion

Diabetes is a complex pathology inducing a great number of factors. To treat it, different approaches are needed and some of the most promising ones have been presented during this conference. Might it be the environment, the patient, or also the cells, an efficient solution to the disease should act at all the levels. This meeting has given a global vision, from the fundamental cellular research to the problematics encountered at the patients’ level.

An event labelled by:

Previous achievements

association@ceed-diabete.org (Claire MASALSKI) — Wed, 20 Jul 2016 09:46:26 GMT

Discover CeeD's presentations and posters.

PRESENTATIONS

2023

European Association for the Study of Diabetes (EASD), Hambourg, Germany, October 2023

Unique signature of circular RNA in skeletal muscle of different insulin sensitivity , M. Yepmo

IPITA, San Diego, USA, October 2023

ILV-001 a highly promising therapeutic agent for islet transplantation. A. Langlois, A. Grabarz, M. Pinget, K. Bouzakri.

Société Francophone du Diabète (SFD), Montpellier, France, March 2023

Peptide X, un inhibiteur de la protéine MP001 prometteur pour améliorer la survie et la fonction des îlots pancréatiques humains. A. Langlois, M. Kanzaki, G. Bechtluft, M. Pinget, K. Bouzakri.

2022

EASD, Stockholm, Sweden, September 2022

Peptide X, a promising inhibitor of MP001 protein which improves human pancreatic islet survival and function. A. Langlois, M. Kanzaki, G. Bechtluft, M. Pinget, K. Bouzakri

2021

Société Francophone du Diabète (SFD), Strasbourg, France, March 2021

Un composant du sécrétome musculaire au secours de la greffe d’îlots pancréatiques. A. Langlois, W. Bietiger, C. Peronet, G. Bechtluft, M. Pinget, K. Bouzakri.

2017

IPITA, Oxford, UK, June 2017

Improvement of pancreatic islet survival, function and angiogenesis targeting Prolylhydroxylases. A. Langlois, W. Bietiger; C. Peronet, C. Sookhareea, C. Mura; E. Maillard, M. Pinget, S. Sigrist and K. Bouzakri.

2016

Transplantation Research & Techniques, Atlanta, USA, October 2016

Stimulation of islet revascularization modulating HIF-1α expression using siPHD3. A. Langlois, E. Maillard-Pedracini, M. Prinz, R. Beaurepère, W. Bietiger, C. Sookhareea, C. Mura, N. Jeandidier1, M. Pinget, S. Sigrist.

2014

AIDPIT, Igls, Austria, January 2014

Pro-angiogenic effect of liraglutide in a model of intrahepatic transplantation of rat pancreatic islets: role of oxidative stress. A. Langlois, S. Dal-Ros, K. Vivot, W. Bietiger, C. Mura, C. Peronet, E. Seyfritz, C. Dollinger, E. Maillard, M. Pinget, N. Jeandidier, S. Sigrist.

2013

IPITA, Monterey, USA, September 2013

Role of oxidative stress in the pro-angiogenic effect of liraglutide on Rat pancreatic islets. A. Langlois, S. Dal-Ros, W. Bietiger, C. Mura, E. Seyfritz, C. Dollinger, M. Pinget, N. Jeandidier, S. Sigrist.

2011

CTS-IXA, Miami, USA, October 2011

Stimulation of VEGF secretion in rat pancreatic islets using Liraglutide. A. Langlois, K. Vivot, N. Jeandidier, W. Bietiger, C. Dollinger, M. Pinget, S. Sigrist
Influence of islet culture on angiogenic and inflammatory reaction. A. Langlois, K. Vivot, N. Jeandidier, C. Dollinger, W. Bietiger, M. Pinget, S. Sigrist

IPITA, Prague, Czech Republic, June 2011

Role of islet culture on angiogenic and inflammatory mechanisms. A. Langlois, C. Dollinger , W. Bietiger , K. Vivot , N. Jeandidier , M. Pinget, S. Sigrist.

2010

Alfediam - Société Francophone du Diabète (SFD), Lille, France, March 2010

Effet comparé de la surexpression du VEGF par la Deferoxamine ou l’infection adénovirale sur le contrôle métabolique de rats diabétiques après transplantation d’îlots pancréatiques. A. Langlois, W. Bietiger, M. Pinget, L. Kessler, N. Jeandidier, S. Sigrist.

AIDPIT, Igls, Austria, January 2010

Identification of new therapeutic targets to increase islet vascularization during transplantation. A. Langlois, W. Bietiger, M. Pinget, S. Sigrist.
Comparative effect of VEGF overexpression using DFO or adenoviral infection on metabolic control of diabetic Rats after islets transplantation. A. Langlois, W. Bietiger, M. Pinget, L. Kessler, N. Jeandidier, S. Sigrist.

2009

Alfediam - Société Francophone du Diabète (SFD), Strasbourg, France, March 2009

Amélioration de la revascularisation des îlots pancréatiques après transplantation : approche génétique ou pharmacologique ? A. Langlois, W. Bietiger, E. Seyfritz, E. Maillard, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

ATTD, Athens, Greece, February 2009

Optimization of pancreatic islets revascularization after transplantation: Pharmacological approach or gene therapy? A. Langlois, W. Bietiger, E. Seyfritz, E. Maillard, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

2008

Alfediam - Société Francophone du Diabète (SFD), Brussels, Belgium, March 2008

Approche pharmacologique ou génique pour la surexpression du VEGF par les îlots pancréatiques au cours de la transplantation ? A. Langlois, W. Bietiger, E. Seyfritz, K. Mandes, E. Maillard, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

AIDPIT, Igls, Austria, January 2008

Pharmacologic approach or gene therapy for VEGF overexpression in pancreatic islets during transplantation? A. Langlois, W. Bietiger, E. Seyfritz, K. Mandes, E. Maillard, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

2007

IPITA, Minneapolis, USA, September 2007

Overexpression of VEGF in vitro using deferoxamine: new drug to increase islet vascularisation during transplantation. A. Langlois, W. Bietiger, K. Mandes, E. Maillard, M. Pinget, L. Kessler, S. Sigrist.

International Symposium Bioengineering and Regenerative Medicine, Mulhouse, France, September 2007

AIDPIT, Montpellier, France, February 2007

Effect of the deferoxamine in the overexpression of VEGF during islets transplantation. A. Langlois, K. Mandes, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

2006

Alfediam - Société Francophone du Diabète (SFD), Paris, France, March 2006

Surexpression de VEGF au cours de la transplantation d’îlots : thérapie génique ou cellulaire ? A. Langlois, K. Mandes, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist,

AIDPIT, Pisa, Italy, February 2006

Cellular or gene therapy for type 1 diabetic patients: Overexpression of VEGF during islets transplantation. A. Langlois, K. Mandes, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

TONECA, Barcelona, Spain, January 2006

Preservation of islets viability during transplantation: vegf overexpression using cellular or gene therapy. A. Langlois, K. Mandès, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

POSTERS

2023

American Diabetes Association (ADA), San Diego, USA, June 2023

• ILV-001 a highly promising therapeutic agent for islet transplantation. A. Langlois, A. Grabarz, M. Pinget, K. Bouzakri.

• Unique signature of circular RNA in skeletal muscle of different insulin sensitivity. M. Yepmo, E. Meugnier, M. Pinget, K. Bouzakri

Société Francophone du Diabète (SFD), Montpellier, France, March 2023

Résultats d’un dépistage de masse du diabète de type 2 chez 8 354 sujets vivant dans le Grand Est entre 2015 et 2021. M. Pflieger, R. Bidani, S. Ludwig, D. Gras, M. Pinget

2022

Société Française d'Endocrinologie (SFE), Nantes, France, October 2022

Prévention et traitement de la NASH par des myokines. A. Dumond Bourie, JB Potier, A. Fardellas, M. Aouadi et K. Bouzakri

International Liver Congress, European Association for the Study of Liver, London, UK, June 2022

Skeletal muscle-derives myokine affects insulin sensitivity and lipogenesis in a human hepatocytes spheroid model. A. Dumond, J-B. Potier, M. Aouadi, A. Fardellas

Société Francophone du Diabète (SFD), Nice, France, March 2022

La Myokine X, myokine dérivée du triceps, protège les cellules β pancréatiques contre l'inflammation chronique. A. Langlois, B. Zarrouki, J. Cherfan, C. Arous, C. Peronet, H. Hamdard, B. Wehrle Haller, M. Pinget et K. Bouzakri.

2019

EuroDia Meeting, Strasbourg, France, November 2019

Myokine X, a new candidate to improve pancreatic islet survival, function and angiogenesis during transplantation. A. Langlois, G. Desmartin, W. Bietiger, M. Pinget, K. Bouzakri.
Use of targeted mRNA-loaded Extracellular Vesicles (EVs) for the specific delivery to cells and tissue. A. Forterre, JH Wang, A. Delcayre, K. Kim, C. Green, M. D. Pegram, S. S. Jeffrey and AC Matin.
Insulin-resistance induced TNF-alpha in C2C12 increase the release of exosome-like vesicles which affect insulin of pancreatic beta-cells. L. Reininger, A. Jalabert, JP Pais de Barros, V. Bergas, P. Colosetti, N. Akbar, R. Choudhury, M. Pinget, M. L Mizgier, K. Bouzakri and S. Rome
Regulation of exosomes secretion by muscle fiber and insulin sensitivity. ML Mizgier, H Hamdard, M Pinget, K Bouzakri
Preliminary results on the effect of M101, a marine oxygen carrier, on human pancreases cold preservation. F. Lemaire, C. Peronet, K.Bouzakri, S. Sigrist, E. Delpy, F. Zal, M.Pinget and E. Maillard

2017

EuroDia Meeting, Strasbourg, France, November 2017

EASD, Lisbon, Portugal, September 2017

Impact of Prolyhydroxylases proteins on survival, function and angiogenesis in pancreatic islets: A target to improve islets graft? A. Langlois, W. Bietiger; C. Peronet, C. Sookhareea, C. Mura; E. Maillard, M. Pinget, S. Sigrist and K. Bouzakri.

2016

EPITA, Igls, Austria, Janvier 2016

Impact of hyperglycemia on islets revascularization deficiency post intraportale transplantation. A. Langlois , E. Maillard-Pedracini , S. DAL, C. Sookhareea, A. Schaschkow , W. Bietiger, N. Jeandidier, M. Pinget, S. Sigrist

2015

IPITA, Melbourne, Australia, November 2015

Impact of hyperglycemia on islets revascularization deficiency post intraportale transplantation. A. Langlois, S. DAL, C. Sookhareea, A. Schaschkow , E. Maillard-Pedracini, W. Bietiger, N. Jeandidier, M. Pinget, S. Sigrist
Stimulation of islet revascularization modulating HIF-1α expression using siPHD3. A. Langlois, E. Maillard-Pedracini, M. Prinz, R. Beaurepère, C. Mura, W. Bietiger, N. Jeandidier, M. Pinget, S. Sigrist
New strategy of islet viability improvement in bioartificial pancreas using composites islets/MSC-A. A. Langlois, A. Grunenberg, E. Maillard-Pedracini, C. Mura, W. Bietiger, N. Jeandidier, M. Pinget, S. Sigrist.

2014

Société Francophone du Diabète (SFD), Paris, France, March 2014

Effet pro-angiogénique du liraglutide dans un modèle de transplantation intra-hépatique d’îlots pancréatique de Rat: rôle du stress oxydant. A. Langlois, S. Dal-Ros, K. Vivot, W. Bietiger, C. Mura, C. Peronet, E. Seyfritz, C. Dollinger, E. Maillard, M. Pinget, N. Jeandidier, S. Sigrist.
Evaluation des propriétés anti-inflammatoire et anti-oxydante du liraglutide sur des îlots pancréatiques de Rat in vitro. A. Langlois, K. Vivot, S. Dal-Ros, W. Bietiger, C. Mura, E. Seyfritz, C. Dollinger, M. Pinget, N. Jeandidier, S. Sigrist.
Stratégies d’administration du liraglutide pour optimiser la transplantation d’îlots pancréatiques chez le Rat diabétique. A. Langlois, W. Bietiger, C. Mura, C. Peronet, E. Maillard, M. Pinget, N. Jeandidier, S. Sigrist.

AIDPIT, Igls, Austria, January 2014

Evaluation of anti-inflammatory and anti-oxidative properties of liraglutide on Rat pancreatic islets in vitro. A. Langlois, K. Vivot, S. Dal-Ros, W. Bietiger, C. Mura, E. Seyfritz, C. Dollinger, M. Pinget, N. Jeandidier, S. Sigrist
Strategies of liraglutide administration to optimize islet transplantation in diabetic rats. A. Langlois, W. Bietiger, C. Mura, C. Peronet, E. Maillard, M. Pinget, N. Jeandidier, S. Sigrist.

2013

EASD, Barcelone, Spain, September 2013

Role of oxidative stress in the pro-angiogenic effect of liragluitde on Rat pancreatic islets. A. Langlois, S. Dal-Ros, W. Bietiger, C. Mura, E. Seyfritz, C. Dollinger, M. Pinget , N. Jeandidier , S. Sigrist.

2012

Société Francophone du Diabète (SFD), Nice, France, March 2012

Stimulation de la sécrétion de VEGF dans les îlots pancréatiques de Rat par le Liraglutide. A. Langlois , K. Vivot , N. Jeandidier , W. Bietiger , C. Dollinger , M. Pinget , S. Sigrist.

2011

EASD, Lisbonne, Portugal, September 2011

Liraglutide increases VEGF secretion in rat pancreatic islets. A. Langlois, K. Vivot, N. Jeandidier, W. Bietiger, C. Dollinger, M. Pinget, S. Sigrist.

Société Francophone du Diabète (SFD), Geneva, Switzerland, March 2011

Rôle favorable du temps de culture des îlots pancréatiques de Rat sur l’inflammation. A. Langlois, C. Dollinger, W. Bietiger, K. Vivot, N. Jeandidier, M. Pinget, S. Sigrist.
Rôle délétère du temps de culture des îlots pancréatiques de Rat sur les mécanismes angiogéniques. A. Langlois, C. Dollinger, W. Bietiger, K. Vivot, N. Jeandidier, M. Pinget, S. Sigrist.

2010

Alfediam - Société Francophone du Diabète (SFD), Lille, France, March 2010

Identification de nouvelles cibles pharmacologiques pour stimuler la revascularisation des îlots au cours de la transplantation. A. Langlois, W. Bietiger, M. Pinget, S. Sigrist.
Inflammation et transplantation d’îlots pancréatiques : Rôle de la voie de chemokines. K. Vivot, A. Langlois, W. Bietiger, M. Pinget, L. Kessler, S. Sigrist.
Etude des microparticules libérées par les cellules RINm5F soumises à différentes conditions de stress. F. Aboud, A. Langlois, JM. Freyssinet, L. Kessler, F. Toti-Orfanoudakis.

2009

IPITA, Venisa, Italy, October 2009

Identification of new therapeutic targets to increase islet vascularization during transplantation. A. Langlois, W. Bietiger, M. Pinget, S. Sigrist

AIDPIT, Igls, Austria, January 2009

Optimization of pancreatic islets revascularization after transplantation: pharmacological approach or gene therapy? A. Langlois, W. Bietiger, E. Seyfritz, E. Maillard, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist

2008

EASD, Roma, Italy, September 2008

Optimization of pancreatic islets revascularization after transplantation: Pharmacological approach or gene therapy? A. Langlois, W. Bietiger, E. Seyfritz, K. Mandes, E. Maillard, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

2007

Société française d'endocrinologie (SFE), Marseille, France, March 2007

Rôle de la déferoxamine dans la surexpression de VEGF au cours de la transplantation d’îlots. A. Langlois, K. Mandes, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

2006

Alfediam - Société Francophone du Diabète (SFD), Paris, France, March 2006

Immunomodulation des îlots pancréatiques : effet de l’irradiation UVB sur l’activation macrophagique. A. Langlois, G. Guidicelli, K. Mandes, A. Belcourt, M. Pinget, L. Kessler, S. Sigrist.

AIDPIT, Pisa, Italy, February 2006

Immunomodulation of pancreatic islets: Effect of UVB irradiation on macrophage activation. A. Langlois, G. Guidicelli, K. Mandes, M. Pinget, L. Kessler, S. Sigrist.

2005

Société française d'endocrinologie (SFE), Strasbourg, France, October 2005

Immunomodulation des îlots pancréatiques : effet de l’irradiation UVB sur l’activation macrophagique. A. Langlois, G. Guidicelli, K. Mandes, M. Pinget, L. Kessler, S. Sigrist.